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I. Introduction 
Statement of Purpose 
 The purpose of this thesis is to elucidate biochemical and biophysical 
characteristics of various proteins thought to be involved in the etiology of Alzheimer’s 
disease. One theory suggests the main cause of the disorder is the formation of toxic 
oligomers and aggregates following production of the amyloid-beta peptide by the 
enzyme gamma-secretase. The careful characterization of proteins that promote 
amyloid beta production, or confound anti-amyloid drug development will greatly 
contribute to the Alzheimer’s field and aid in the future development of effective 
therapeutics. 
 The first chapter of this thesis introduces the essential features of Alzheimer’s 
disease, the protein components and the confounding factors to drug development. The 
subsequent chapters describe the careful biochemical and biophysical characterization 
of the proteins thought to be related to the disorder. The final chapter discusses the 
conclusions from my experimental studies and future directions suggested by the work 
of this dissertation. 
Introduction to Alzheimer’s Disease 
 As modern medicine and therapeutics evolve, the percentage of people in the 
United States and around the world that die from serious illnesses like heart disease 
and cancers will continue to decrease. In fact, U.S. patients dying from diseases like 
heart disease, stroke and HIV have decreased significantly1 with advances in drug 
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therapies. Patients that die from Alzheimer’s disease (AD) however, are currently on the 
rise and the trend is expected to continue as people worldwide continue to live longer, 
healthier lives. According to reports by the Alzheimer’s Association, it is thought that by 
2050, the number of people over the age of 65 with AD will triple in the United States 
alone.1  These numbers reflect only the United States, but European countries have 
similar trends and as 2nd and 3rd world countries improve healthcare, booms in AD are 
expected in these countries as well.  
 Alzheimer’s disease is the most common form of dementia and is lethal. 
Symptoms of AD are generally characterized by a gradual progression towards 
dementia. In general, the symptoms are: confusion with time and place, difficulty 
completing familiar tasks, trouble understanding spatial relationships, memory loss that 
is disruptive to daily life, problems with planning or problem solving. As the disorder 
progresses symptoms can include new problems with words or speech, impaired 
judgment, social withdraw, and changes in mood and personality.1 Patients typically live 
4-8 years post-diagnosis, although patients can live as long as 20 years with the 
disease, the bulk of the time in the most advanced stage of the disorder. 
 Advanced stage patients require near round the clock caregiving to assist with 
mobility, hygiene, and general wellbeing. The total paid healthcare costs for patients 
with dementia in the US for 2015 was estimated to be greater than $ 225 billion. In 
addition, each year in the US unpaid caregivers provide additional billions of dollars 
worth of care to AD patients often to the detriment of the caregiver’s own health and 
wellbeing. These caregivers report higher levels of stress, depression, and poorer 
physical health than caregivers of the elderly without AD. Nearly 50% of the caregivers 
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had to leave their employment to provide patient care.1 As more people get AD this loss 
of employment could easily become a substantial burden on the world workforce. 
Alzheimer’s Disease Etiology 
 The exact etiology or mechanism of action of AD is unknown. This is one reason 
that despite first being described in 1907, we still do not have a cure for this devastating 
disorder. For many years the only way to concretely diagnose a patient with AD was a 
post-mortem autopsy and notation of severe brain vascularization and atrophy and the 
presence of aggregated protein deposits called “amyloid plaques” and tangles. The 
major component of the tangles was aggregated remains of hyper-phosphorylated tau, 
a microtubule stabilizing protein abundantly expressed in the central nervous system. 2  
The plaque deposits of fibrilized proteins were the best signifier of the disorder. The 
major component of these plaques remained unknown until 1984 when researchers out 
of UCSD, Glenner and Wong, isolated a peptide from patient brains and named it 
amyloid-beta (Aβ). 3  Shortly after that another group determined that the Aβ peptide 
was a cleavage product of the larger protein that they named the amyloid precursor 
protein (APP).4 
 APP as a causative factor in AD was supported by the gene locus of the APP 
gene and the genetic disorder Down’s syndrome or trisomy 21. Researchers found that 
the plaque deposits found in the brains of Down’s syndrome patients and AD patients 
contained the same protein,4 Aβ. The genetic locus of APP is on chromosome 21.5 
Given that Down’s syndrome is a genetic disorder where there is a duplicate of 
chromosome 21, this means these patients have essentially a triple dose of the APP 
protein.6 This overload likely explains the clinical feature that Down’s syndrome patients 
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over the age of 30 have increased amyloid deposits and are likely to present clinical 
symptoms of AD early, in late 40s to early 50s.7 
 APP is proteolytically processed in two potentially competing pathways. When 
APP is cleaved by the enzyme α-secretase, it enters the “non-amyloidogenic pathway” 
where the end product is the APP intracellular domain (AICD) and a small soluble 
peptide called “p3.” The second pathway, the “amyloidogenic pathway” ultimately yields 
the AICD and the Aβ peptide.8 More details on these pathways can be seen in Figure 
1.1. In the non-amyloidogenic pathway, APP is cleaved by α-secretase, a 
metalloprotease, to produce a transmembrane stub called C83. C83 is then cleaved in 
the membrane by γ-secretase to release the AICD and the soluble peptide p3. This p3 
peptide may actually have neuroprotective characteristics.9 The AICD may also have a 
role on cholesterol homeostasis, which will be addressed in a later section. 
 The amyloidogenic pathway is entered8 when APP is processed by the enzyme 
β-secretase, BACE1. BACE1 would be an intriguing therapeutic target as inhibiting this 
reaction would likely favor the non-amyloidogenic pathway and thus limit the amount of 
Aβ.10 After β-secretase cleavage, the transmembrane stub C99 is left in the membrane 
and a soluble fragment sAPPβ is released. There is research that indicates that the 
sAPPβ serves as a ligand and may help to stimulate caspase 6.11 This would suggest 
that perhaps even this soluble domain contributes to apoptosis and thus the neuronal 
degradation seen in AD. The removal of the sAPPβ fragment also serves as a 
sheddase event required before γ-secretase can cleave the transmembrane stub C99.12, 
13 C99 is then cleaved in the membrane by γ-secretase to produce the AICD and the Aβ 
peptide.8  
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 Due to the promiscuous nature of the γ-secretase complex,13 there is not a single 
cleavage product of C99. Instead, the transmembrane segment of C99 is processively 
cleaved with little specificity.14, 15 Processive cleavage results in Aβ peptide of differing 
lengths. The most abundant form of the Aβ peptide is the Aβ40 with Aβ42/38 being less 
prevalent. While not the major product Aβ42, and the ratio of Aβ40:Aβ42 is thought to be a 
major pathological marker.16-19 Genetic mutations and system changes that shift the 
ratio towards Aβ42 are considered to be AD risk factors.20-23  
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Figure 1.1- APP Processing. APP can be cleaved in two competing pathways. The 
“non-amyloidogenic” pathway is entered when APP is cleaved by α-secretase to 
produce the fragment soluble APPα (sAPPα) and the transmembrane stub C83. 
C83 is cleaved in the membrane by γ-secretase to produce two soluble peptides, 
p3 and the AICD. The “amyloidogenic pathway” begins when APP is cleaved by 
the β-secretase enzyme BACE1 to produce the transmembrane stub C99 and the 
fragment soluble APPβ (sAPPβ). C99 is then also cleaved by γ-secretase to 
produce two soluble peptides, Aβ and the AICD. The Aβ peptide continues on to 
form the Aβ oligomers implicated in AD etiology. 
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Given that the Aβ42 form seems to be more prone to aggregation,24 it is interesting that 
new research has indicated that the early stage of soluble Aβ oligomers/aggregates 
(Figure 1.1) may actually be responsible for the neurotoxicity seen during AD 
progression, not the large insoluble plaques.25 This production of the Aβ peptide is 
thought to be the center of the Amyloid Cascade Hypothesis. 26 A brief visual 
representation of the amyloid cascade hypothesis can be seen in Figure 1.2.27, 28 In this 
model, the production of the Aβ peptide is the central cause of the neuronal damage 
and eventual dementia seen in AD. There is a great deal of research that supports this 
claim and has been extensively reviewed.26-33 That is not to say, however, that there are 
not detractors of the theory. Given that the amyloid cascade theory has been the major 
research focus for nearly a decade, and that there is still no cure some researchers are 
beginning to question the principle of having Aβ at the center of the theory and suggest 
researchers would be better suited to explore alternate etiological paradigms such as 
inflammation or oxidative damage as the major causative factor.32, 34 
 In spite of possible detractors, a great deal of work has been directed towards 
understanding the structural, biochemical, and biophysical characteristics of the protein 
C99 with the intention of using this in vitro information in the broad scheme of 
understanding APP processing and the etiology of AD. In the Sanders lab, extensive 
research has been conducted to determine how to express and purify the full-length 
C99 protein in a lipid mimetic, as well as to assess the backbone protein dynamics and 
the positioning of C99 relative to the membrane.35 The structure of C99 in a detergent 
micelle and the novel fact that C99 will directly and specifically bind the molecule 
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cholesterol has also been determined.36 Additional work to look at the competition 
between C99-cholesterol binding vs. dimerization37 and how membrane bilayer 
thickness impacts C99 position relative to the membrane38 has also been carried out. 
New work, geared towards new lipid mimetics that may better replicate cellular 
conditions is currently underway (unpublished). Overall, the Sanders group has carefully 
characterized the full-length C99 molecule and this characterization contributes to the 
scientific understanding of the field overall. 
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Figure 1.2- Amyloid Cascade Hypothesis.  In this theory, AD etiology is based 
around the production of the Aβ peptide and the oxidative damage, stress, and 
neuronal damage that follows and how subsequent steps are the formation of tau 
tangles and neuronal dysfunction. This model is based on original figures in 
Broerson et. al. (2010)27 and Karren et. al. (2011).28  
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APP and Cholesterol 
 The exact role that cholesterol plays in the etiology of Alzheimer’s disease is still 
ambiguous. There is however, a stunning amount of research that has linked 
cholesterol and Alzheimer’s disease. The initial evidence linking AD and cholesterol was 
published in 1994 when rabbits fed a high cholesterol diet ended up with plaques similar 
to those seen in AD patients brains39 and humans with advanced coronary heart 
disease.40 Since then, the effect of cholesterol has been studied largely in animal 
models and in vitro systems and has been extensively reviewed.35, 41-49 This section will 
briefly touch on the relationship between AD and cholesterol and how different domains 
of APP can impact cholesterol homeostasis and biosynthesis. Cholesterol and lipid 
biosynthesis seem to be entangled with AD on multiple levels. 
 There are only two very strongly correlated risk factors of late onset AD (LOAD). 
The first is advanced age. The second is a genetic risk factor. ApolipoproteinE (ApoE) is 
a lipoprotein that transports cholesterol between neuronal cells. There are 4 genetic 
variations of this protein, and genetic screens and GWAS studies have indicated that 
the ApoE ε4 allele is one of the biggest risk factors for the development of LOAD beside 
old age,50-52 although the ApoE ε4 allele alone is not sufficient to cause AD.53 
 Much of the relationship between cholesterol and AD may be due to APP and the 
proteolysis products of APP cleavage. Given that research suggests that the 
amyloidogenic pathway largely occurs in cholesterol and sphingholipid-rich lipid raft 
microdomains that include the enzymes β- and γ-secretase42, 54, 55 the connection is 
strengthened. More information on lipid rafts and APP processing can be found in the 
next section. APP processing is closely regulated by cholesterol and APP fragments 
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regulate lipid homeostasis. Intracellular cholesterol regulates APP processing through 
the ACAT enzyme, an important acyltransferase involved in bile acid biosynthesis.56 
Expression of APP reduced HMG-CoA reductase regulated cholesterol biosynthesis, 
while the reduction of APP increased cholesterol biosynthesis. This change in 
cholesterol biosynthesis was likely mediated through an interaction between APP and 
the protein SREBP.57 Therefore, APP regulates SREBP mediated cholesterol 
biosynthesis in cultured neurons, and the inhibition of cholesterol turnover/homeostasis 
inhibited neuron function.57 
 The products of APP proteolysis also play a role in cholesterol synthesis or 
homeostasis. Wang et. al. found in 2014, that the soluble sheddase product of APP 
processing in the lumen of the secretory pathway had a differential control of cholesterol 
synthesis through the interaction with SREBP.58 The intracellular domain of APP, the 
AICD and the binding partners Fe65 and Tip60 work jointly to suppress expressing 
LRP1, an ApoE receptor that mediates cholesterol uptake and thus regulates 
cholesterol homeostasis.59 Although, as with much of the research in the relationship 
between cholesterol and AD, this role has been questioned due to reported differences 
in the phosphorylation state of the AICD, as well as the role of the binding partners in 
signal transduction.60 
 The Aβ peptide is also strongly linked with cholesterol in results documented in 
the literature. Brain ischemia from atherosclerosis may promote APP expression which 
increases Aβ oligomers and senile plaque and neurofibrillary tangle depositions.61, 62 
Research indicates that lipids and cholesterol may control or enhance Aβ 
aggregation.63-66 Aβ may also function as an inhibitor of HMG-CoA reductase, the rate 
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limiting enzyme in the cholesterol biosynthesis pathway.67  A brief map of the putative 
roles of cholesterol in AD can be seen in Figure 1.3. 
 Given the interconnectedness of APP and cholesterol, it may be unsurprising that 
the cholesterol lowering drugs called statins have an interesting impact on AD. After a 
series of retrospective studies,61 it was reported that statin reduced the risk of LOAD by 
approximately 50%.68 The exact mechanism of this is unknown. One possible 
mechanism is: decreases in intracellular cholesterol from statins breaks down lipid rafts 
and thus favors the non-amyloidogenic pathway, and lowers the risk of AD.42, 54, 69 Given 
the above information, it seems possible that APP functions in part as a cholesterol 
sensor.35 This is again supported by the specific interaction between C99 and 
cholesterol.36 These factors make statins and cholesterol analogs very attractive 
therapeutic possibilities that could be used to modulate the levels of Aβ production or 
even limit its aggregation. 
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Figure 1.3- Map of how cholesterol can influence Alzheimer’s disease. 
Cholesterol influences AD in multi-pronged way. It is the major component of 
lipid rafts that promotes the amyloidogenic pathway processing. Deposition of 
cholesterol in blood vessels can lead to atherosclerotic plaques and brain 
hyperfusion. The combination of these factors leads to brain damage and AD.  
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Gamma Secretase 
 The gamma-secretase enzyme (γ-secretase) plays a prominent role in the 
ongoing research on Alzheimer’s disease. This enzyme complex is considered to be 
part of the intramembrane cleaving proteases or I-CLiPs family of enzymes.70 This 
family of enzymes, including rhomboid and Site 2 Protease (S2P),71 is capable of 
catalyzing a hydrolytic reaction within the hydrophobic domain of the lipid bilayer. The 
rhomboid catalytic site is a dyad of asparagine residues in the transmembrane region of 
the protein.72 This is of particular interest because it is different from the typical catalytic 
modality. The catalytic component of γ-secretase, the protein presenilin, is a member of 
this I-CLiP family, the catalytic dyad a more traditional aspartyl dyad.73  
 γ-secretase was characterized to be part of AD pathogenesis in 2006.74 γ-
secretase is an unusual I-CLiP member because it is a four component complex. 
Presenilin is the catalytically active component, the other components are Nicastrin, 
anterior pharynx defective-1 (APH-1), and presenilin enhancer-2 (PEN2).75 Nicastrin is 
thought to be involved in substrate recognition;76 APH-1 largely serves as scaffolding 
and to stabilize the complex.77 PEN-2 stimulates the required auto-catalysis of the 
presenilin protein and is an essential part of the complex.78-80 Biochemical analysis has 
demonstrated that the stoichiometry of the complex is a 1:1:1:1 tetrameric complex.81 
The cleaved presenilin is stabilized by an interaction with the PEN2 component.82 A 
cartoon of the γ-secretase complex can be seen in Figure 1.4. 
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Figure 1.4- Gamma Secretase Components. The tetrameric gamma secretase 
complex has 4 components, all of which are transmembrane proteins. The 
catalytically active component presenilin (red, the active site residues are marked 
with stars), the scaffolding unit APH-1 (green), substrate selector, Nicastrin 
(purple) and PEN-2 (orange) responsible for stabilization and the autocatalysis of 
presenilin can be seen with the correct number of helices.  Only nicastrin has a 
substantial extracellular domain. 
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 One feature of this enzyme complex is the lack of substrate specificity. As of 
2011 there were over 90 proteins thought to be substrates of γ-secretase. Table 1.1 
contains known γ-secretase substrates.83 What regulates the enzyme/substrate 
interaction is not known, although there are some intriguing theories.  In 2013, the 
Urban lab proposed that intramembrane proteolysis is not a feature of substrate affinity, 
but instead is limited by the kinetics of the reaction itself.84 The Urban study, done on 
the rhomboid protease, GlpG has significant ramifications for other members of the I-
CLiP family. Their data would suggest that γ-secretase cleaves any membrane protein 
that fits within the active site and that there is no specific regulation. If this is the case, it 
leads to the question of why would there be multiple isoforms of both presenilin and 
APH-1, and further why would these different enzyme components have slightly 
different function.85, 86 There are many other ways that γ-secretase may also be 
regulated. One possibility is that γ-secretase function is regulated by spatial segregation 
of enzyme and substrate.87 Another plausible regulatory mechanism is that the lipid 
microenvironment itself helps to regulate γ-secretase function.  
 Research has shown that active γ-secretase is associated with “lipid rafts.”88-90 
Lipid rafts can be defined as short-lived, ordered lipid microdomains enriched with 
cholesterol and sphingomyelin.91 γ-secretase is sensitive to the membrane thickness as 
well as the chain length, saturation and lipid head group.92-94 This suggests that γ-
secretase is more sensitive to lipid environment, and that its activity can be regulated by 
the lipid composition. Thus the lipid microenvironment and the cellular compartment that 
γ-secretase is occupying at the time of enzyme substrate interaction may regulate 
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function. The different lipid composition present in the different cellular compartments95 
only serves to further support the idea that γ-secretase regulation may be a factor of 
both lipid microdomain identity and spatial sequestration. Lastly, given the wealth of 
information about the role of cholesterol in AD, it is not challenging to speculate about 
the role that cholesterol plays in regulating γ-secretase function and thus the 
development and progression of AD. It is important to note however, that none of these 
possible regulatory mechanisms invalidate the kinetic studies of the rhomboid protein; 
they instead suggest for γ-secretase there are additional levels of complexity that should 
be considered. 
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Table 1.1- List of known γ-secretase substrates as of 2011* 
1 Alcadein α 24 EphrinB2 47 LRP2 (megalin) 70 Ptprz 
2 
Alcadein γ 
(calsyntenin) 25 ErbB4 48 LRP6 71 RAGE 
3 APLP1  26 GHR  49 MUC1 72 RPTPκ 
4 APLP2 27 HLA 50 N-cadherin 73 RPTPµ 
5 ApoER2  28 HLA-A2 51 Nav-β1 74 ROBO1 
6 AβPP 29 IFNaR2 52 Nav-β2 75 SorC3 
7 Betacellulin (BTC) 30 IGF-1R 53 Nav-β3 76 SorCS1b 
8 Betaglycan 9. 31 IL-1R1 54 Nav-β4 77 SorLA (LR11) 
9 CD43  32 IL-1R2 55 Nectin-1α 78 Sortilin 
10 CD44 33 IL6R 56 Neuregulin-1 79 Syndecan-1 
11 CSF1R 34 IR 57 Neuregulin-2 80 Syndecan-2 
12 CXCL16 35 Ire1α 58 Notch 1 81 Syndecan-3 
13 
CX3CL1 
(fractalkine)  36 Ire1 β 59 Notch-2 82 Tie1 
14 DCC 37 Jagged2 60 Notch-3 83 Tyrosinase 
15 Delta1  38 KCNE1 61 Notch-4 84 TYRP1 
16 Desmoglein-2 39 KCNE2 62 NPR-C 85 TYRP2 
17 DNER 40 KCNE3 63 NRADD 86 Vasorin 
18 Dystroglycan  41 KCNE4 64 p75NTR 87 VE-cadherin 
19 E-cadherin 42 Klotho 65 PAM 88 VEGF-R1 
20 EpCAM 43 L1 66 PLXDC2 89 VLDLR 
21 EphA4 44 LAR 67 
Polyductin 
(PKHD1) 90 GluR3 
22 EphB2 45 LRP1(LDLR) 68 
Protocadherin-α4 
(Pcdh-α4) 91 GnT-V 
23 EphrinB1 46 LRP1 b 69 
Protocadherin-γ-
C3 (Pcdh-γC3) 
  *Based on data complied by Annakaisa Haapasalo and Dora M. Kovacs in the 2011 review “The many 
substrates of presenilin/γ-secretase.”83 
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 Until 2014, there was no high-resolution structure of γ-secretase. This was, in 
part, due to the inability to produce sufficient quantities of functional enzyme complex 
for structure determination. The next challenge was a technical one; γ-secretase was 
too large for NMR, too flexible for x-ray crystallography and too small for cryo-EM (cryo-
electron microscopy). In 2015, with the use of a direct electron detector and the 
collection of nearly 1 million particles, the Shi research group was able to reconstruct a 
cryo-EM structure of the full and active γ-secretase complex. This structure resolved at 
~3.4Å, and the helices are assigned. This assignment allows the active site of the 
enzyme complex to be seen in depth for the first time.96 A second work, elaborating on 
the structure shows the different conformations that the γ-secretase catalytic subunit 
can have.97 Figure 1.5 is the 3.4Å structure of γ-secretase. As in Figure 1.4, presenilin is 
colored red, Nicastrin is colored purple, PEN2 is orange and APH-1 is green. The active 
site aspartate residues are colored cyan. These new structures will allow for a careful 
examination of the active site in order to better understand the γ-secretase mechanism 
of action. It will also allow for docking studies of γ-secretase and the varied substrates to 
get a better understanding of how γ-secretase functions. 
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Figure 1.5- Cryo-EM structure of γ-Secretase. Adapted from PDB: 5A63. Presenilin 
is colored red. The active site aspartate residues are colored cyan. Nicastrin is 
purple, APH-1 is green and PEN2 is orange. This depiction of the structure is 
modified from the original publication (Cryo-EM structure of the human gamma-
secretase complex at 3.4 angstrom resolution) by coloring and the display of the 
active site.   
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Preventing APP Processing 
 
 Curing Alzheimer’s disease by either preventing or clearing the Aβ 
oligomers/deposits has long been a dream in the Alzheimer’s field. Unfortunately, it is 
far more challenging a feat than originally thought.  Since the amyloid cascade 
hypothesis first took center stage,26 there have been 3 major approaches to “curing AD.” 
The first approach, which has resulted in 2 failed clinical trials, was to use anti-Aβ 
antibodies that were supposed to induce phagocytic clearance of the amyloid plaques 
and thus prevent the cognitive problems of AD.98-101  Both of these clinical trials ended 
with no significant cognitive improvement seen in trial participants. The failure of these 
expensive clinical trials has many researchers questioning if the antibody approach is 
the correct avenue.102 The other two approaches are designed to prevent or mitigate the 
production of Aβ. The first, gamma-secretase inhibitors (GSI) are defined as small 
molecules that inhibit the function of γ-secretase completely. The second, gamma 
secretase modulators (GSM) moderate the processive cleavage of the enzyme, thus 
changing the length of the Aβ product.103 
 The first generation of the GSI molecules were exceptionally useful in the 
analysis of how γ-secretase functions, but were not part of an actual AD clinical trial. In 
1999 the Selkoe lab developed a series of inhibitors based on the Aβ42 cut site. These 
inhibitors were designed to resemble the transition state of the C99 cut site.104 It was 
this inhibitor binding that helped to confirm that presenilin was the catalytic part of γ-
secretase.105, 106 The inhibitor L-685.458 was synthesized around the same time, and is 
a potent inhibitor of γ-secretase cleavage.107 This is one of the γ-secretase inhibitors still 
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used in γ-secretase research. The excellent 2009 review by Anthony Kreft has more 
information about the chemistry and the development of these early γ-secretase 
inhibitors.108 
 A second cohort of allosteric GSIs bind to presenilin.108 This family includes the 
molecule DAPT, another potent γ-secretase inhibitor used in research.109 These 
inhibitors broadly inhibit γ-secretase function and are not substrate specific.110 
Semagacestat, an allosteric inhibitor, made it to Phase 3 clinical trials before they had to 
be cancelled.111 Trial participants experienced skin problems and a wealth of physical 
issues, but perhaps the most troubling was a decline in cognitive capabilities. It was 
determined that the inhibition of Notch signaling was the likely culprit. A third cohort of 
inhibitors was produced that were thought to be “Notch sparing.” These inhibitors 
supposedly only inhibited APP cleavage and the Notch processing was modulated not 
stopped. Despite this, clinical trials had to be halted due to Notch induced toxicity.112 It 
is possible that the “Notch sparing” effects were overestimated and were never 
promising candidates.110 
 Drugs that mitigate γ-secretase function instead of inhibiting it are called gamma-
secretase modulators: GSMs. Many of this drug class can change the length ratio of the 
generated Aβ peptides. One subset of these GSMs are based on NSAID drugs 
including ibuprofen and naproxen.110 Another class are heterocyclic GSM not derived 
from NSAIDs. Interestingly, these different classes of drugs seem to have a similar 
effect on γ-secretase function. The heterocyclic GSM lowers Aβ40/42 and increases the 
amount of Aβ37/38.113 The NSAID-GSM also lowers Aβ42 and increases Aβ38 while not 
impacting the cleavage of the Notch substrate making the drug specific to C99.110, 114 It 
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is possible that some of these NSAID-GSM drugs order lipid bilayers like cholesterol do, 
and this may factor into their mechanism of action.115 
 In 2008, a paper published by the Golde lab reported that a specific subset of 
NSAID-based GSM compounds has a direct and specific interaction with C99, which 
defines the C99 specificity.116 The Sanders lab used NMR and purified C99 to 
demonstrate that any interaction between these drugs and C99 was weak and non-
specific and that there may have been confounding aggregation in the original paper.117 
This report incited controversy, and in 2010 and 2011 the Multhaup group published two 
papers that reinforced their interpretation that the NSAID-GSM drugs directly interacted 
with the Aβ portion of C99. They used NMR, SPR and a bacterial reporter gene 
dimerization assay.118, 119 These contrasting results encouraged the Sanders group to 
return to the NSAID-GSMs. They used the drug sulindac sulfide and the Aβ and 
ultimately saw no specific interaction between the drug and the peptide. The results of 
their study ultimately led them to conclude there was no interaction between the GSMs 
and Aβ, and thus, that complex formation could not be the underpinning of GSM 
mechanism of action and specificity.120 
 To date, none of these NSAID-based GSMs have made it to clinical trial and, 
given the conflicting reports on the mechanism of action for the Notch sparing behavior,  
researchers are still actively looking for a target that may be the key for APP-specific 
druggability.  
Gamma Secretase Activating Protein 
 The sole focus on APP processing has not yielded a viable drug or drug target to 
date. Now researchers are attempting to find drugs or proteins that will impact 
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accessory proteins or currently unknown protein cofactors. In 1999, the Greengard 
group developed a cell free assay to study Aβ generation and trafficking that had a 
pronounced ATP energy requirement.121 As a follow up study, in 2003 the same group 
thought to use small molecules with ATP activity as a method for inhibiting Aβ.122 They 
selected the tyrosine-kinase inhibitor imatinib mesylate, or Gleevac, a well-known 
cancer drug. It binds to the ATP binding site of the kinase and inhibits activity. The 
results from this study suggested that not only does γ-secretase cleavage have an ATP 
requirement, but the addition of imatinib mesylate was able to prevent the production of 
the Aβ peptide.122 Imatinib mesylate inhibition of APP processing also had no effect on 
the processing of Notch.122 The mechanism of action of the selective inhibition was 
unknown but a promising avenue of research despite the fact that imatinib mesylate will 
not cross the blood brain barrier (BBB). 
 In 2010, the Greengard group published a new study in Nature that suggested 
they had determined the imatinib mechanism and discovered a novel therapeutic 
target.123 The Greengard group created an immobilized imatinib pull-down assay, to try 
and identify any proteins that would bind to this drug. In this assay, the components of γ-
secretase were isolated along with a new protein that ran at approximately 16kDa on an 
SDS-PAGE gel. This gel band was identified using mass spectrometry as the previously 
uncharacterized pigeon homologue protein (PION). The protein was then characterized 
as the gamma secretase activating protein (GSAP).123 The imatinib/γ-secretase 
interaction is dependent on GSAP, when GSAP is knocked down, the interaction 
between the drug and the complex is reduced. Further, when GSAP was knocked down 
with siRNA, the levels of Aβ were significantly reduced, while imatinib alone didn’t 
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change anything. This suggests that GSAP modulates the inhibitory function of imatinib. 
In mouse models, GSAP knockdown reduces the plaque load in mouse brains. When 
recombinant GSAP was added to cell culture, the concentration of Aβ increased while 
AICD levels were reduced. This would suggest GSAP differentially affects the 
processivity of γ-secretase.123 Finally, in cells expressing the Notch extracellular 
truncation (NEXT), the γ-secretase substrate, the levels of the Notch intracellular 
domain (NICD), a γ-secretase cleavage product, was not altered by either the presence 
of recombinant GSAP or by GSAP knock-down.123 
 This APP specificity was essential to the use of GSAP as a therapeutic target.  
The authors then sought to hypothesize on the specificity of GSAP modulation. 
Immunoprecipitation (IP) experiments suggested that GSAP exists in a complex with γ-
secretase, acting as a co-factor. Further IP experiments and preliminary domain 
mapping suggest that GSAP functions by directly interacting with the cytosolic 
juxtamembrane segment of C99.123 The C99:GSAP complex became a very interesting 
structural target in the Sanders group in light of the structure of C99 that our lab had 
been working on at the time. Work done to replicate the interaction between C99 and 
GSAP as well as to structurally characterize this interaction will be detailed in depth in 
Chapter 2, and future thoughts about the protein and eventual controversy regarding the 
overall reproducibility of the GSAP narrative will be discussed in Chapter 5. 
Notch 
 As detailed in previous sections, the sheer number of γ-secretase substrates and 
the challenge of finding an APP-specific drug preventing γ-secretase cleavage as a 
therapeutic strategy of AD has caused a significant bottleneck. Arguably, the γ-
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secretase substrate that has caused the most significant problems in AD drug 
development98, 100, 101, 111, 112 is the Notch family of proteins. 
 Notch was first discovered and studied in the context of Drosophila genetics and 
in embryogenesis. The Notch gene was named for the “notch” winged fly phenotype 
found by Morgan.124, 125 The role Notch plays in development and embryogenesis was 
determined when it was found that loss of the Notch gene function was responsible for 
an embryonic lethal alteration to the nervous system.126 The Notch gene and notch 
signaling occur in all vertebrate organisms.127-130 Notch is the critical mediator of binary 
cell fate decisions as well as developmental lateral inhibition. In vertebrates, Notch 
signaling has been implicated in a diverse array of patterning choices. Some of these 
include inner ear hair cell formation, pancreatic cell production, intestinal cell 
differentiation, and immune cell selection.131-134 Notch signaling also controls 
neurogenesis, axon and dendrite growth, and synapse plasticity, as well as neuronal 
death.135-143 
 There is one Notch gene in Drosophila melanogaster, and as organism 
complexity increases so do the number of homologs. Caenorhabditis Elegans has 2 
homologs, and humans have 4.144-148 One significant difference between the homologs 
beyond tissue expression variation and function is differences in the domains of the 
protein. Notch is a type 1 membrane receptor with a series of modular domains with 
distinct function. Notch organization can be seen in Figure 1.6. There are eight discreet 
domains, extracellularly; there are the EGF repeats, three LNR repeats, and the 
heterodimerization domain. The LNR repeats and the heterodimerization domain make 
up the negative regulatory region (NRR). Then there is the transmembrane segment. 
	   27 
On the intracellular side, there is the RAM domain, a series of ankyrin repeats, a 
transcriptional activation domain (TAD) and a PEST domain. The first domain, EGF 
repeats, is the ligand-binding domain. Mammalian Notch proteins have between 29 and 
36 repeats, and ligand binding generally occurs through an interaction with repeats 11-
13. Many of the EGF repeats bind calcium, and this binding regulates signaling 
activity.149, 150 The EGF repeats are also heavily glycosylated, and this glycosylation can 
moderate the signaling.151 A family of glycosyltransferase proteins change the 
fucosylation pattern at specific EGF repeats and are able to tune how sensitive the 
receptor is to the ligand.152 Canonical Notch ligands bind the receptor through EGF-like 
domains on both Notch and ligand.153, 154 Non-canonical ligands are not going to be 
discussed but were reviewed by Michael Wang in 2011.155 
 The NRR region is a very important segment of the protein. This segment 
contains both the heterodimerization domain and three LNR repeats. It is called the 
NRR because the fold of this segment mask the S2 cut site that is the committed step of 
the Notch signaling pathway and regulates the signaling.140, 156 The heterodimerization 
domain is the site of the initial S1 cleavage step, where the intact Notch protein is 
cleaved in the Golgi extracellularly by a furin-like convertase.143 This cleavage event 
leaves the protein as a heterodimer with the extracellular domain (ECD) linked to the 
combined TM and intracellular domains in a non-covalent manner.157, 158 Questions 
regarding how the NRR functioned were answered by a structure of the complete NRR 
domain.156, 159 In this structure, the 3 LNR repeats wrap around the heterodimerization 
domain and the  S2 cut-site and prevent functional exposure, (see middle panel in 
Figure 1.6).159 
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Figure 1.6- Domains of Notch1. Notch 1 has 8 distinct domains.  Major soluble 
domains structures have been determined. Known structures of complete 
domains are aligned with model representation. Structures colored by 
hydrophobicity in Pymol. PDB accession codes: 4D0E, 3IO8, 2F8Y, and 3V79 (top 
down). 
 
 
	   29 
 
 The transmembrane segment (TM) links the extracellular domain to the 
intracellular. Despite the fact that TM cleavage is as an essential part of the signal 
activation; the TM segment has not been extensively studied until recently (see Chapter 
3 and 4). It is known that the TM segment is cleaved in the membrane by γ-secretase,160 
releasing a small extracellular peptide (Nβ)161 and the large Notch intracellular domain 
(NICD).92, 162-164 
 The first segment of the NICD is the RAM domain. This stands for RBPJ-
associated molecule, and this is where the NICD binds with the transcription partner 
RBP-Jκ (also known as CSL).165, 166 It is thought that until binding of the complex 
occurs, the RAM domain is unstructured.167 Following the RAM domain is a series of 7 
ankyrin repeats that are required for signal transduction.168 This segment has contacts 
with the RBP-Jκ partner and is essential for the recruitment of the third transcription 
factor partner Maml (Mastermind in Drosophila).167, 169, 170 The penultimate segment of 
the NICD is the transcriptional activation domain. This portion of the molecule is where 
the transcriptional activity occurs and can happen in an autonomous manner.171-174 The 
final segment is the PEST domain. The PEST stands for a protein sequence rich in 
proline (P), glutamic acid (E), serine (S) and threonine (T). These sequences are 
generally associated with proteins that are rapidly degraded.175 This domain is 
phosphorylated by CDK8 and targeted for polyubiquitination and proteosomal 
degradation after signaling. Rapid degradation of the NICD transcription factor serves to 
regulate gene transcription and to rapidly respond to the cellular input during 
development. This allows for careful control of the duration of Notch signaling.171, 176, 177 
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Figure 1.7- Notch Processing. Notch is cleaved at site S1 to form a heterodimer. 
The heterodimer is transported to the plasma membrane. A trans binding with a 
ligand induces the opening of the negative regulatory region. Opening of the 
negative regulatory region exposes the S2 cut site to a metalloprotease and is 
cleaved allowing the extracellular domain to be endocytosed by the ligand. The 
NEXT is cleaved in the membrane to release the NICD and a soluble peptide Nβ.  
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 The life cycle of Notch signaling/ processing is mapped out in Figure 1.7. Notch 
begins in the ER as a holoprotein (1). In the Golgi the protein is extensively 
glycosylated, and cleaved by a furin-like convertase, resulting in a dimer of two non-
covalently linked portions (2). The heterodimer is trafficked to the plasma membrane 
where signaling can begin (3). In general, the signaling pathway is initiated when 
mature Notch at the plasma membrane has a trans binding interaction with a membrane 
bound protein ligand from a neighboring cell to the extracellular EGF domain of the 
Notch protein (4).150 There are also data that suggest that a cis interaction is actually 
inhibitory.178 This binding event triggers trans-endocytosis of the Notch-bound ligand.179  
 The role of endocytosis in the signaling pathway is very important. In canonical 
Notch signaling the ligand is also a type 1 membrane protein on a neighboring cell. After 
ligand binding, productive signaling generally requires the endocytosis of the ligand 
back into the cell.180, 181 Endocytosis induces a force on the Notch extracellular domain 
that mechanically extends the negative regulatory region of the protein including 
residues 1449-1731.156 This force exposes the previously buried S2 cut site (4) to the 
ADAM 10/17 metalloprotease,182-184 which cleaves the protein to release the 
extracellular domain (5) in the committed step of the signaling pathway. Research has 
indicated that after the Notch extracellular domain has been cleaved at S2, the 
ectodomain is endocytosed into the signal-donor cell.179, 181 
 While the exact order of the subsequent processing, trafficking, and cleavage 
steps are still being investigated, Notch is endocytosed and cleaved in its TMD by γ-
secretase (6),160 releasing a small extracellular peptide (Nβ)161 and the large Notch 
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intracellular domain (NICD) (7).92, 162-164 After translocation to the nucleus, the NICD 
forms a transcriptional activator complex with CSL168 and MAML185 that targets a 
number of different genes.186, 187 Further exploration behind the mechanism of Notch 
processing is important both to understanding Notch biology and to a better 
understanding of the mechanism of action of γ-secretase and thus AD.  
Summary 
 The work in this dissertation is an exploration of the proteins related to AD and 
how increasing the biochemical and biophysical knowledge can enhance the field’s 
understanding of AD etiology. This work includes careful protein expression and 
biochemistry, NMR, circular dichroism, and computational analysis of protein structure. 
Chapter 2 describes the characterization of GSAP, leading to results that challenge 
what had been originally published. Chapter 3 describes the work to purify the 
transmembrane segment of Notch, assign the backbone, and analyze the protein 
topology and backbone dynamics. Chapter 4 provides a careful comparison of the 
structure, membrane tolerance, and cholesterol binding of the Notch TM segment with 
the protein C99. This comparison will help to differentiate these two proteins in a way 
that may lead to a Notch sparing γ-secretase inhibitor. 
	   33 
II. Purification and Characterization of the Human γ-
Secretase Activating Protein1 
Introduction 
 Alzheimer’s Disease (AD) is a devastating neurodegenerative disease that 
impacts millions of people worldwide at enormous personal and economic cost.188 
Unfortunately, there is currently no cure or effective treatment, but researchers have 
made significant progress in characterizing the pathophysiology of AD.189 The most 
widely-accepted hypothesis for disease etiology revolves around the amyloid precursor 
protein (APP).29 APP is cleaved by β-secretase to generate its 99 residue 
transmembrane C-terminus (C99), which is then cleaved by γ-secretase to produce 
amyloid beta (Aβ) peptides of different lengths. These peptides form neurotoxic 
oligomers that go on to deposit as neuritic plaques, the pathological markers of the 
disease.  
 Inhibition of the heterotetrameric γ-secretase to block cleavage of C99 would 
reduce Aβ production.75, 190, 191 Unfortunately, γ-secretase has numerous substrates and 
has not, so far, been an effective therapeutic target because of the important role that 
its cleavage of other substrates, particularly Notch, plays in cellular differentiation.192 As 
such, there is great interest in exploring how to prevent or modulate C99 cleavage 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 This work is adapted from Deatherage CL, Hadziselimovic A, Sanders CR Purification and 
characterization of the human γ-secretase activating protein. Biochemistry. 2012 Jun 26;51(25):5153-9. 
doi: 10.1021/bi300605u 
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without inhibiting cleavage of other γ-secretase substrates. This imperative resulted in 
the discovery of the γ-secretase activating protein (GSAP). 
 GSAP was first described by He et al. 2010.123 A previous study had shown that 
the Abl kinase inhibitor imatinib decreases Aβ production, likely by inhibiting γ-secretase 
activity.122 The search for the imatinib target led to photo-labeling of the C-terminal 
domain of the uncharacterized Pigeon Homolog Protein (PION). The domain is 
proteolytically released from PION under cellular conditions, the resulting protein being 
referred to as GSAP. GSAP appears to form a ternary complex with γ-secretase and 
C99, as determined through immunoprecipitation reactions and pull-down assays. 
Knockdown of GSAP through siRNA in N2a cells selectively lowered Aβ levels, and did 
not reduce the cleavage of other γ-secretase substrates. GSAP knockdown also 
reduced Aβ plaque burden in a mouse model of AD.123 These data suggest that GSAP 
may selectively promote Aβ production by promoting γ-secretase cleavage of C99, 
making GSAP a potential AD drug target. Since the initial discovery of GSAP, one 
additional research paper has been published, which characterized the 
immunohistochemical distribution of GSAP in the brains of AD patients.193 GSAP 
immunoreactivity was observed in four distinct morphological structures present in 
different regions of the brain in AD patients, one of these structures was largely unique 
to AD brains as compared to age-matched control brains. GSAP immunoreactivity was 
also detected in close proximity to presenilin (PS1, a component of γ-secretase) as well 
as in close association with Aβ-containing senile plaques. While recombinant 
expression and purification of GSAP was briefly mentioned in these reports, methods 
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were not provided. This paper details the expression, purification, and characterization 
of GSAP. 
Materials and Methods 
Materials.  BL21 (DE3) and Rosetta (DE3) competent cell lines and the pET32a vector 
were purchased from EMD Millipore (Darmstadt, Germany). The restriction enzymes 
NdeI, XhoI, BamI and NcoI were purchased from New England Biolabs (Ipswich, MA). 
The 15NH4Cl used to isotopically label GSAP was purchased from Cambridge Isotope 
Laboratories (Andover, MA). Ampicillin and MEM vitamin solution were purchased from 
Cellgro (Manassas, VA). Imatinib mesylate was purchased from Selleck Chemical 
Company (Houston, TX). Ni-NTA chromatography resin was purchased from Qiagen 
(Valencia, CA). The protease inhibitor P8849, Empigen BB detergent (n-dodecyl-N,N-
dimethylglycine) and imidazole (≥99% titration grade) were purchased from Sigma-
Aldrich (Saint Louis, MO). n-Dodecylphosphocholine (DPC), lyso-
myristoylphosphatidylglycerol (LMPG) and isopropyl β-D-1-thiogalactopyranoside 
(IPTG) were purchased from Affymetrix/Anatrace (Maumee, OH). 
Cloning and Construction of the vectors encoding His-tagged forms of GSAP.  GSAP 
corresponds to the 121 residue (amino acids 733-854) C-terminus of the human pigeon 
homolog protein (PION). The GSAP gene (NM_017439.3) was purchased from 
GeneCopoeia (Rockville, MD). Two constructs were prepared, with either N- or C-
terminal His purification tags (His6 and His10, respectively). To construct the C-terminally 
His10-tagged construct, the GSAP DNA was digested with NdeI and XhoI after PCR 
amplification, and was then was inserted into the pET-21b vector. The N-terminal His6-
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tagged construct was similarly engineered using NcoI and XhoI restriction enzymes and 
a pET-16a vector. Constructs were confirmed by DNA sequencing. 
 A second set of constructs was prepared to replicate as closely as possible the 
constructs used in He et al. 2010.123 The first was a pET-32a vector encoding a fusion 
protein in which thioredoxin is linked to the N-terminus GSAP through an intervening 
His6 tag. As with the His6-tagged constructs expressing only GSAP, the thioredoxin 
fusion protein was constructed from the DNA digested with BamI and XhoI after PCR 
amplification of the GSAP gene and was then inserted into the pET-32a vector. A 
second construct, expressing only thioredoxin, was prepared as a control by inserting a 
stop codon just before the start of the GSAP coding region in a pET-32a vector. This 
was accomplished using standard site-directed mutagenesis methods (QuickChange, 
Agilent Technologies, Santa Clara, CA). 
Expression of GSAP in E. coli.  Vectors were transformed into E. coli BL21(DE3) cells, 
which were plated onto ampicillin LB-agar plates and then incubated overnight at 37°C. 
A single colony was used to inoculate a 5ml culture of LB media containing 100µg/ml of 
ampicillin. The starter culture was grown for eight hours at 37°C. A 1 L culture of M9 
minimal media was prepared using 15NH4Cl for isotopic labeling. The medium for large-
scale growth also included ampicillin, glucose, MEM vitamins, 0.1 mM CaCl2, and 1 mM 
MgSO4. Starter culture (1.2 ml) was added directly to the 1 L culture and the cells were 
grown at room temperature until the OD600 reached 0.8. Protein expression was induced 
using 1 mM IPTG, and the cells were harvested by centrifugation 24 hours after 
induction. Expression of the recombinant GSAP was confirmed by Western blotting 
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using a monoclonal anti-5X His mouse antibody (Cell Signaling Technology, Danvers, 
MA). 
Purification of N- and C-Terminally His6-Tagged GSAP.  The harvested cells were 
weighed and lysed in 20 ml of lysis buffer (75 mM Tris, 300 mM NaCl, 0.2 mM EDTA, 
pH 7.8) per gram of cells. Also added to the following concentrations were 5 mM 
MgAcetate, 2 mg/ml of lysozyme, 0.2 mg/ml DNase and RNase, and 50 µl of protease 
inhibitor per gram of cells. The suspension was tumbled for 90 minutes at room 
temperature. Following tumbling, cells were further disrupted by five-minute probe 
sonication with a 50% duty cycle at approximately 57 watts using a Misonix 
(Farmingdale, NY) sonicator. The lysate was centrifuged at 20,000 rpm in a Beckman-
Coulter (Indianapolis, IN) JA 25.5 rotor (approximately 48,000xg) and the pellet, which 
includes inclusion bodies, was retained. The inclusion bodies containing GSAP were 
solubilized in 20 ml of lysis buffer per original gram of cells using 3% Empigen (%v/v), a 
harsh detergent. This solution was tumbled at room temperature until a clear mixture 
was observed (approximately 4.5 hours). The sample was then centrifuged to remove 
any remaining insoluble particulates. Ni-NTA resin (1.2 ml per gram of cells) was 
equilibrated with buffer A (40 mM HEPES, 300 mM NaCl pH 7.8). The supernatant was 
tumbled with the resin for one hour at room temperature. The resin was loaded into a 
column and sequentially washed with buffer A containing 3% Empigen (%v/v), and 
buffer A containing 30 mM imidazole and 1.5% Empigen (%v/v), respectively, to elute all 
non-His10-tagged proteins from the resin. Empigen was then exchanged for the 
detergent n-dodecylphosphocholine (DPC) by re-equilibrating the column with 12 
column volumes of 20 mM phosphate, pH 7.2, containing 0.5% DPC (%w/v). GSAP was 
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eluted from the column with 250 mM imidazole containing 0.5% DPC (%w/v), pH 7.8. 
Purification was monitored by A280. After purification, 2 mM DTT was added to the 
sample to reduce disulfide bonds. 
 The purification process was monitored by SDS-PAGE gel electrophoresis. 
Electrophoresis experiments were carried out using an Invitrogen (Grand Island, NY) 
Novex-Mini Gel system and NuPAGE 4-12% Bis-Tris polyacrylamide gels and MES 
running buffer.  
Purification of Thioredoxin-His6-GSAP Fusion Protein.  The purification of Trx-His6-
GSAP was alluded to but not described in the original paper,123 but is similar to the 
His10-GSAP purification strategy described above (personal communication). Trx-His6-
GSAP expressing cells were grown, harvested, and lysed as above. After lysis, the 
supernatant was collected and bound to Ni-NTA resin equilibrated in 50 mM phosphate, 
500 mM NaCl pH 7.8. The slurry tumbled for one hour at room temperature. The resin 
was rinsed with 50 mM phosphate, 500 mM NaCl pH 7.8 and then washed with 50 mM 
phosphate, 500 mM NaCl, 40 mM imidazole pH 7.8 to remove any remaining non-
specifically bound protein. Trx-His6-GSAP was eluted from the column with 50 mM 
phosphate, 500 mM NaCl, 300 mM imidazole pH 7.8. The eluate was concentrated to a 
volume below 5 ml and filtered with a 0.2 µm filter. The sample was then subjected to 
size exclusion chromatography using a HiPrep™ Sephacryl™ S300 16/60 gel filtration 
column on an AKTAprime-plus FPLC eluted with 20 mM HEPES, 200 mM NaCl, 1 
mM EDTA pH 8.0. 
Circular Dichroism (CD) Spectroscopy.  Protein samples were purified as described 
above and were exchanged into a 25 mM sodium phosphate buffer, pH 7.5, containing 
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0.5% DPC using a PD-10 desalting column (Bio-Rad). The sample and buffers were 
passed through a 0.2 µm filter before CD data collection. Far-UV CD data was collected 
from 190 to 260 nm on a Jasco (Easton, MD) J-810 CD spectropolarimeter. Data from 
five scans were averaged together and blank-corrected. 
Solution NMR Spectroscopy.  For NMR spectroscopy, the pH of GSAP was adjusted to 
7.5 and D2O to 10% was added, followed by concentration through ultrafiltration using 
an Amicon Centrifugal Filter unit molecular weight cut-off 10,000 Da (Millipore, Billerica, 
MA). An HSQC spectrum was collected on a 600 MHz Bruker AVANCE III spectrometer 
at 298 K using TopSpin3 and a standard Bruker pulse sequence. 
Titration of C99 by GSAP.  Uniformly 15N-labeled C99 with a His6-containing purification 
tag at its C-terminus was expressed and purified as described in Beel et al. 2008,35 with 
a few minor variations. Cultures of E. coli with an expression vector encoding C-
terminally His6-tagged human C99 were grown at 37°C in minimal media with Cellgro 
MEM vitamins and induced at OD600= 0.8 using IPTG, at 18°C overnight. Cells were 
lysed and inclusion bodies were isolated and washed three times with lysis buffer 
followed by sonication and recentrifugation. Tagged C99 was then purified using Ni-
NTA affinity chromatography into 0.05% LMPG micelles with 250 mM imidazole pH 7.8. 
After purification, U-15N-C99 was buffer-exchanged and centrifugally concentrated in 
Amicon concentrators to a final condition of 0.6 mM, with 2.5% LMPG and 100 mM 
imidazole. The pH was adjusted to 7.5 using glacial acetic acid and ammonium 
hydroxide. Unlabeled GSAP was prepared as described above using 0.05% LMPG as 
the detergent for the final purification steps. The purified protein was buffer-exchanged 
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to reduce the imidazole concentration to 100 mM and concentrated to 0.45 mM. The pH 
was adjusted to 7.5 and LMPG was added to a final concentration of 2.5%. 
 For titrations, NMR samples were prepared with 0.1 mM C99 in each sample and 
increasing molar ratios GSAP up to 4:1 GSAP:C99, in 100 mM imidazole, 2.5% or 10% 
LMPG. 1H,15N-TROSY spectra were collected at 298 K for each sample to determine 
the effect of GSAP on the chemical shifts of the peaks in the C99 spectrum.  
Titration of Imatinib by GSAP.  GSAP was prepared as described, except that the final 
buffers were made using D2O. The sample was concentrated and passed over a PD-10 
desalting column to remove all traces of imidazole. This sample contained 0.325 mM 
GSAP in 25 mM sodium phosphate in D2O, 1% DPC, pH 7.5 and served as a stock 
solution for the titration. Starting with a solution of 339 mM imatinib mesylate in DMSO, 
a 1 mM stock solution of the drug in 1% DPC (%w/v) in D2O was prepared. The NMR 
samples were prepared with 50 µM imatinib, 25 mM imidazole and increasing amounts 
of GSAP up to a four-fold molar excess. The imatinib 1-D 1H NMR peaks not obscured 
by detergent and protein were monitored for changes with increasing amounts of GSAP 
using a 600 MHz magnet at 298 K.  
 
Results 
Expression and Purification of GSAP.  The GSAP domain of the PION 123 was cloned 
into pET vectors. Two constructs, one with an N-terminal (pET16) His6- and one with a 
C-terminal (pET21) His10- purification tag were cloned. Both constructs overexpressed 
well in different strains of E. coli (BL21(DE3) and Rosetta(DE3)). It was found that the 
N-terminally tagged construct was highly expressed, but was highly unstable and prone 
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to aggregation. For this reason, the experiments here were conducted using the C-
terminally tagged construct, which behaved more favorably. 
 Following expression, cell lysis, and centrifugation, GSAP was located primarily 
in inclusion bodies (IB), despite culturing the cells in minimal medium at room 
temperature, conditions sometimes found to promote folding of unstable or misfolding-
prone recombinant proteins. Consequently, IB solubilization and protein refolding was 
necessary. Solubilization methods tested included dissolution of IB in 8M urea and 0.2% 
sodium dodecyl sulfate (SDS), both together and separately, followed by removal of the 
denaturant under different buffer and pH conditions, ranging from pH 5.5 to 7.8. 
Unfortunately, despite much effort all refolding attempts resulted in precipitation of 
GSAP. For further details on refolding attempts and outcomes, see Table 2.1.  
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Table 2.1- Summary of Attempts to refold Non-immobilized GSAP  
Experiment Method Outcome 
Dialysis-Based 
Refolding  
After solubilization of IB by SDS and 
8M urea, sample was dialyzed against 
decreasing amounts of denaturant at 
pH 7.8. 
GSAP precipitated out of 
solution during dialysis in 0M 
urea. 
Dialysis-based 
refolding after 
purification in 
denaturant 
  IB were solubilized in 8M urea 
overnight, followed by metal ion 
affinity chromatography-based 
purification of GSAP in the presence 
of 8M urea. After purification, the 
denatured protein was dialyzed 
against successively decreasing 
amounts of urea. This was preformed 
in different buffer conditions at pH 5.5, 
6.5 and 7.8. 
Purified GSAP eluted cleanly 
from the nickel column and 
was soluble indefinitely in 8M 
urea. Protein began to 
precipitate during the 4M 
urea dialysis step, ending 
with a total loss of GSAP due 
to precipitation by the final 
0M urea stage. 
Rapid dilution 
refolding after 
purification 
  IB was solubilized overnight in 8M 
urea, and then purified as usual in 8M 
urea. After purification, the urea-
denatured protein was slowly added 
drop-wise into a large volume of 
rapidly stirring buffer containing 50 
mM HEPES, 300 mM NaCl, and 400 
mM L-Arginine 
Protocol initially seemed to 
be effective; there was no 
visible precipitation in the 
large rapidly stirring volume. 
However, when sample 
concentration was initiated 
through both centrifugal and 
stirred cell concentration the 
protein catastrophically 
precipitated from solution. 
Refolding after 
purification in 
detergent 
After solubilization of IB by SDS and 
8M urea, sample was bound to 
column and purified in 0.2% SDS. 
SDS was then dialyzed out of solution 
at pH 7.8 
The protein precipitated out 
of solution as SDS was fully 
dialyzed out of the sample. 
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 Additional experiments were carried out in an effort to refold the protein, this time 
with GSAP immobilized by binding to Ni-NTA resin through its His10 tag. Inclusion 
bodies were solubilized with 8M urea and 0.2% SDS and incubated with Ni-NTA resin. 
The first on-column refolding test involved the stepwise removal of SDS and urea from 
the solution bathing the resin. Subsequent on-column refolding attempts and the 
outcome are listed in Table 2.2. 
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Table 2.2- On-column refolding attempts 
Experiment Method Outcome 
Refolding on the 
column by urea 
removal 
After solubilization of IB by SDS 
and 8M urea, sample was bound 
to column and refolded with 15% 
glycerol and decreasing amounts 
denaturant on the column. 
GSAP could not be eluted 
from the resin after all of the 
denaturant had been rinsed 
away.  
Purification with 
DM  
IB solubilized with Empigen, bound 
to the metal ion affinity resin, 
followed by equilibration and 
attempted elution with a solution 
containing the mild non-ionic 
detergent, β-decylmaltoside.  
GSAP failed to elute from 
column with 250 mM 
imidazole and 0.5% DM at pH 
7.8.  
Purification 
without detergent  
IB were solubilized with Empigen, 
followed by binding of GSAP to 
metal ion affinity resin and 
successive re-equilibration with 
DPC and DM solutions, with a 
detergent free solution, followed by 
attempted elution of the protein 
using a detergent-free buffer. 
GSAP failed to elute from 
column upon attempted 
elution using 250 mM 
imidazole, pH 7.8.  
 
	   45 
 
 After complete removal of denaturant, an attempt was made to elute the protein 
from the column with 250 mM imidazole, pH 7.8. However, GSAP did not elute, 
indicating insolubility in a denaturant-free and detergent-free elution buffer. Based on 
the knowledge that GSAP can be solubilized using a harsh detergent (SDS), additional 
attempts were made to refold GSAP in the presence of a milder detergent. 
 Inclusion bodies were solubilized using the harsh zwitterionic detergent Empigen 
and GSAP was then associated with the nickel resin. The detergent present in the 
solution that bathes the Ni-NTA-bound GSAP was then switched from Empigen to one 
of several detergents: DPC, lyso-myristoylphosphatidylglycerol (LMPG) or 
decylmaltoside (DM), followed by attempted elution using 250 mM imidazole in that 
same detergent solution. It was found that GSAP could not be eluted in DM detergent 
micelle solutions, but did elute when either DPC or LMPG solutions were used. Both of 
these detergents have previously been widely used as membrane mimetics in studies of 
membrane proteins.194 Figure 2.1 shows an SDS-PAGE gel that documents protein 
purification. The elution fraction has only two bands, which have been confirmed by 
mass spectrometry to be the monomer and dimer forms of GSAP. The dimer band is 
likely due to the presence of the single cysteine at amino acid position 32, as this band 
is absent in the presence of a reducing agent. The total yield of purified protein was 
approximately 15 mg per liter of culture.  
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Figure 2.1- GSAP Purification. A 4-12% polyacrylamide gel was stained with 
Coomassie R-250 brilliant blue, with lanes: 1) SeeBlue Plus 2 protein molecular 
weight markers. 2) Whole cell lysate solubilized with 4M urea and SDS. 3) 
Sonicated cell lysate further solubilized with 4M urea and SDS. 4) Cellular 
supernatant after centrifugation. 5) Insoluble inclusion bodies solubilized with 
SDS. 6) Purified protein fraction after elution with 250mM imidazole elution plus 
0.5% DPC. All samples were first mixed with an SDS loading buffer prior to 
loading on the gel. (M) monomeric GSAP and (D) dimeric GSAP, as confirmed by 
mass spectrometry. 
  
	   47 
 
 These results indicate that GSAP is highly prone to form insoluble aggregates. 
Despite extensive testing of refolding conditions we found the protein could be 
solubilized only in the presence of detergents or denaturing agents. 
 We next tested a fusion protein form of GSAP. In previous work,123 recombinant 
GSAP was expressed as a fusion protein with thioredoxin, a widely used fusion partner 
for enhancing the solubility and stability of partner proteins.195, 196 We therefore 
constructed and tested a thioredoxin-His6-GSAP-thioredoxin fusion protein. We found 
that the fusion protein also expressed primarily into inclusion bodies. A small fraction 
that expressed in soluble form in the supernatant was associated with Ni-NTA resin, but 
could not then be eluted from the column in the absence of a harsh detergent, such as 
SDS. The amount of protein that was purified without detergent was negligible. 
 We also attempted to generate soluble GSAP without a fusion partner in the 
commercial competent cell line SoluBL21™ (AMS Biotechnology, El Toro, CA). This cell 
line has been modified to enhance the solubility of difficult proteins and to allow for 
soluble expression where no soluble expression is seen in standard competent cell 
lines. When expressed in SoluBL21 cells, GSAP was initially soluble based on detection 
of a GSAP band on an SDS-PAGE gel in the supernatant of the cell lysate after 
centrifugation. However, after binding to the nickel resin followed by elution of all 
impurities in a low concentration imidazole buffer, GSAP failed to elute from the nickel 
resin in the presence of 250 mM imidazole. Application of SDS to the resin released the 
protein (data not shown). This suggests that while expression conditions can be found 
that initially produce a soluble form of GSAP, the protein is highly susceptible to 
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aggregation. This result implies that a propensity of GSAP to aggregate is an intrinsic 
property of this protein. 
 
Characterization of Solubilized GSAP.  The properties of GSAP were examined in 
detergent-containing solutions in which the protein was soluble. Secondary structure 
predictions indicate that GSAP is largely α-helical with stretches of random coil or 
unstructured loops between helices. Near-UV CD spectroscopy in the 250-310 nm 
range (25 mM NaPO4 pH 7.5) revealed a flat spectrum, providing no evidence for stable 
tertiary structure (data not shown). The far-UV CD spectrum collected under the same 
sample conditions shows a pattern consistent with mostly helical secondary structure 
(Figure 2.2). Analysis of this spectrum using the secondary structure prediction server 
K2D3 suggests that GSAP is 92% helical.197 
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Figure 2.2- Estimation of secondary structure from CD data. This spectrum 
indicates that GSAP is largely α-helical with approximately 92% helicity based on 
analysis using the K2D3 secondary structure prediction server. The data 
represents an average of 5 scans. 
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 Two-dimensional 1H,15N-HSQC NMR spectra are routinely used to provide 
general insight into protein structure. All NMR spectra of GSAP-containing samples 
were collected at pH 7.5 because the protein precipitated when reduced to a neutral or 
acidic pH. The HSQC spectrum of 15N-GSAP in DPC micelles is shown in Figure 2.3 
and is poorly dispersed, showing only a fraction of the expected 126 backbone amide 
peaks. This spectrum is consistent with GSAP being largely α-helical but lacking well-
defined tertiary structure, suggestive of a molten globular protein. 
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Figure 2.3- 600MHz spectrum of GSAP. The sample contains ca. 300 µM uniformly 
15N-labeled GSAP in 0.5% DPC, pH 7.5, 2 mM DTT and 10% D2O at 298 K. The 
protein precipitated when the pH was reduced to neutral or acidic values. 
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 GSAP has previously been shown to bind both the small molecule kinase 
inhibitor imatinib and the 99 residue transmembrane C-terminal domain of the amyloid 
precursor protein (C99), which serves as the substrate for γ-secretase cleavage to 
produce the amyloid-β polypeptides.123 However, in neither case is it clear whether 
binary GSAP-imatinib or GASP-C99 complexes are formed, or whether they form 
complexes only in the presence of a tertiary partner such as γ-secretase. We therefore 
tested whether recombinant GSAP can form binary complexes with either imatinib or 
GSAP. 
 1H,15N-HSQC NMR spectra of 150 µM isotopically-labeled GSAP were collected 
in the absence and presence of a 1:1 molar ratio of imatinib. No shifts in GSAP 
resonances were seen upon addition of imatinib, as shown in Figure 2.4. In the reverse 
experiment, 1D NMR spectra were taken of 50 µM imatinib upon titration with increasing 
amounts of GSAP. Addition of GSAP to a 4X molar excess relative to the drug did not 
significantly affect the imatinib peaks (Figure 2.5). The results suggest that affinity 
between GSAP and imatinib under the tested conditions is weak or non-existent.  
 To test for complex formation between C99 and GSAP, 1H,15N-HSQC NMR was 
used to monitor titration of uniformly 15N-labeled C99 by increasing molar ratios of 
unlabeled GSAP. These experiments were initially carried out in 2.5% (w/v) LMPG 
micelles. Under these conditions only modest and non-saturable changes were seen in 
backbone amide 1H,15N peak positions (Figure 2.6), consistent with non-specific or 
weak interactions between these two proteins under the conditions of this experiment.  
 
	   53 
 
Figure 2.4.  GSAP interaction with imatinib. An overlay is shown of 600 MHz 
HSQC NMR spectra of U-15N-GSAP and no imatinib (black) and of GSAP in the 
presence of 1:1 molar ratio of imatinib (red). These samples contained 0.15 mM 
GSAP in 0.5% DPC, pH 7.5, 2 mM DTT, and 10%D2O at 298 K. 
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Figure 2.5.  Imatinib titration by GSAP. The aromatic regions of the 1D 1H NMR 
spectra of 50 µM imatinib are shown as a function of increasing GSAP 
concentrations: 0 µM, 25 µM, 50 µM, 100 µM, 200 µM. Spectra were acquired in 
the presence of 1% DPC and 100% D2O at pH 7.5 and 298 K and normalized to an 
internal standard. The listed ratios are the GSAP:imatinib mole to mole ratios. 
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Figure 2.6.  Titration of U-15N-C99 by GSAP. The lower portion represents 
backbone amide peaks from most residues except for glycines, while the upper 
portion shows the region of the spectrum dominated by glycine resonances. The 
samples contained 2.5% LMPG, pH 7.5, at 298 K. The listed ratios in the upper 
panel are the C99:GSAP mole to mole ratios. 
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 Indeed, while the GSAP interaction domain on C99 was proposed to be localized 
to residues 725-735 in the juxtamembrane cytosolic domain 123, peaks from this domain 
were no more likely to undergo large shifts in response to GSAP than peaks found in 
the transmembrane domain (residues 700-723) for from the extracellular domain of C99 
(residues 672-699), the latter of which is located on the other side of the membrane 
from GSAP under physiological conditions. An additional titration was completed in 
which the same protein concentrations were used but the detergent concentration was 
increased to 10% LMPG. Under these conditions little to no chemical shift changes 
were seen for C99 peaks upon titration by GSAP. The fact that the GSAP-induced 
changes in the spectrum seen at 2.5% LMPG in Figure 2.6 can be eliminated by 
increasing the micelle concentration (at fixed protein concentration) suggests that GSAP 
has some affinity for the micelle surface that leads to non-specific interaction between 
GSAP and C99 when both are confined to the same micelle, an interaction that can be 
minimized by simply adding excess (C99-free) micelles, to which GSAP will redistribute. 
These results indicate that any binding of GSAP to C99 in LMPG micelles is either non-
specific or very weak. These results do not, of course, rule out the possibility that GSAP 
and C99 do specifically and avidly interact, but only when both are bound to γ-
secretase. 
Discussion 
 The notion that GSAP represents a protein that can be targeted by an already-
approved drug to reduce production of the amyloid-β polypeptides is extremely 
appealing. Accordingly, there is a compelling impetus to conduct biochemical and 
biophysical studies of the structure and interactions of this protein. Unfortunately, based 
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on the work presented here, working with GSAP is likely to be challenging. It appears to 
be insoluble in many conditions and was seen to be molten globular under detergent 
micellar conditions in which it is soluble. These observations hold regardless of the 
nature of the protein construct, regardless of the E. coli expression strain, and 
regardless of the refolding methods and final solution composition. While we cannot rule 
out the possibility that a refolding method and/or solution conditions may ultimately be 
found in which GSAP is both soluble and well folded, we were not able to identify any 
such conditions despite considerable effort.  
 Under conditions in which GSAP is solubilized by the presence of DPC micelles it 
was seen to be a mostly α-helical protein, but did not form well-ordered tertiary 
structure. It was also observed that under micellar conditions GSAP does not undergo 
specific association with either imatinib or the C99 domain of the amyloid precursor 
protein. It does not appear that the molten globular form of GSAP can be induced to 
adopt stable tertiary structure by interaction with either of these potential binding 
partners. 
 Despite the failure in this work to observe formation of well-ordered tertiary 
structure by GSAP or complex formation with either imatinib or C99 titrations, our 
results are not definitively negative. We cannot rule out the possibility that an 
unidentified refolding pathway and/or folding-favorable final solution conditions exist that 
we have not discovered. We also cannot rule out the possibility that GSAP is subject to 
an unidentified post-translational modification under native cellular conditions that is 
required for folding or solubility in detergent-free solutions. While GSAP was not seen to 
form binary complexes with either imatinib or C99, it may do so under cellular 
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conditions, perhaps as a result of ternary complex formation with an additional binding 
partner such as γ-secretase. 
 Our results should not be taken to imply a challenge of the data or interpretations 
regarding the GSAP protein as presented in previous work.122, 123 The previous studies 
were carried out primarily using cell-based methods involving model mammalian cell 
lines. However, for those considering the pursuit of biophysical studies on this protein, 
our results suggest that work with recombinant GSAP may prove difficult. We were 
unable to find conditions in which this protein is water soluble to an appreciable degree 
unless detergent micelles were used to facilitate solubilization, presumably by stabilizing 
a hydrophobic surface on GSAP that otherwise drives aggregation. When solubilized, 
GSAP was found to be mostly helical, though it did not adopt a stable tertiary structure. 
Nevertheless, we cannot rule out the possibility that further exploration of expression, 
purification, and protein refolding methods may eventually lead to a form of GSAP that 
is soluble, folded, and competent to bind imatinib and/or C99.  
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III. Notch Transmembrane Domain: Secondary Structure and 
Topology2 
Introduction 
 The Notch signaling pathway is essential to development, neuronal maintenance, 
and hematopoiesis. Notch signaling also controls neurogenesis, synaptic plasticity, 
axonal and dendritic growth, and neuronal death.135-143 In this pathway the Notch 
receptor (Figure 3.2A) is cleaved in its luminal domain by a furin-like convertase in the 
Golgi.143 This cleavage event leaves the protein as a heterodimer with the extracellular 
domain (ECD) linked to the combined TM and intracellular domains.157, 158 The protein is 
then transported to the plasma membrane. Trans binding of a membrane bound protein 
ligand from a neighboring cell to the extracellular EGF domain of the Notch protein150 
triggers a trans-endocytosis of the Notch-bound ligand.179 This induces a force on the 
NOTCH ECD that mechanically extends the negative regulatory region of the protein 
including residues 1449-1731.156 This force exposes the previously buried S2 cut site 
(Figure 3.2B) to the ADAM 10/17 metalloprotease,182-184 which cleaves the protein to 
release its ECD in the committed step of the signaling pathway.  
 While the exact order of the subsequent processing, trafficking, and cleavage 
steps is still being investigated, Notch is endocytosed and cleaved in its TMD by γ-
secretase,160 releasing a small extracellular peptide (Nβ)161 and the large Notch 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2	  This chapter consists of work adapted from	  Deatherage CL, Lu Z, Kim JH, Sanders CR. Notch 
Transmembrane Domain: Secondary Structure and Topology. Biochemistry. 2015 Jun 16;54(23):3565-8. 
doi: 10.1021/acs.biochem.5b00456. 	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intracellular domain (NICD).92, 162-164 After translocation to the nucleus, the NICD forms 
a transcriptional activator complex with CSL168 and mastermind  (MAML in mammals)185 
that targets a number of different genes.186, 187 The signaling cascade is terminated 
when the NICD C-terminal PEST domain is phosphorylated by CDK8 and targeted for 
polyubiquitination and proteosomal degradation.171, 176, 177 Researchers have explored 
the structure of the water- soluble domains of Notch protein associated proteins.156, 159, 
169, 198-202 However, the NOTCH TM and flanking juxtamembrane (TM/JM) domains 
have not been examined. 
 As noted, cleavage of this domain is an essential step in the Notch signaling 
pathway and the prevention of this event can cause significant dysregulation and 
disease.203, 204 Moreover, toxicity caused by inhibition of gamma-secretase cleavage of 
the NOTCH TMD has stymied efforts to prevent or treat Alzheimer’s disease by 
inhibiting gamma-secretase cleavage of the amyloid precursor protein.110 In this paper, 
we present the purification and preliminary structural characterization of the combined 
Notch TM/JM domains. 
Materials and Methods 
Cloning of the Combined Notch1 Transmembrane and Juxtamembrane (TM/JM) 
Domains. Three segments of the Notch1 gene were synthesized (1721-1764, 1721-
1815, and 1721-1850). (Eurofins Genomics Huntsville, AL). To construct the N-
terminally MGHHHHHH-tagged constructs the Notch1 each gene segment was ligated 
into a pTrcHis vector as an NcoI-HindIII fragment. The synthesized 1721-1850 construct 
was further modified using standard site-directed mutagenesis to produce additional N-
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terminal His6-tagged constructs of varying lengths by the insertion of a stop codon at 
different positions (1759, 1765, 1772, and 1791).  
 
Expression of Notch1 in E. coli.  Vectors were transformed into E. coli BL21(DE3)star 
cells, which were plated onto ampicillin LB-agar plates and then incubated overnight at 
37°C. A single colony was used to inoculate an 8 ml starter culture of LB media 
containing 100µg/ml of ampicillin. The starter culture was grown overnight at 37°C. A 1 
L culture of M9 minimal media was prepared using 15NH4Cl for isotopic labeling. The 
media was split between two 2.8L Fernbach culture flasks, each with 500ml. The 
medium for large-scale growth also included 100µg/ml ampicillin, 4mg/ml glucose, MEM 
vitamins, 0.1 mM CaCl2, and 1 mM MgSO4. Starter culture (4 ml) was added directly to 
the 0.5L culture and the cells were grown at 37°C until the OD600 reached 0.8, at which 
point protein expression was induced using 1 mM IPTG and the temperature was 
dropped to 25°C. The cells were harvested by centrifugation 20 hours after induction. 
Expression of the recombinant Notch was confirmed by Western blotting using a 
monoclonal anti-5XHis mouse antibody (Cell Signaling Technology, Danvers, MA). 
 
Purification of N-Terminal His6-Tagged Notch1 TM/JM (1721-1771).  The harvested 
cells were weighed and lysed in 20 ml of lysis buffer (75 mM Tris, 300 mM NaCl, 0.2 
mM EDTA, pH 7.8) per gram of cells. To this was added MgAcetate to 5 mM, 2 mg/ml of 
lysozyme, 0.2 mg/ml DNase and RNase, and 1mM PMSF, as well as 50 µl of a 
protease inhibitor cocktail (Sigma-Aldrich, P8849), per gram of cells. The suspension 
was tumbled for 30 minutes at 4°C.  Powdered DTT was then added to a concentration 
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of 1mM before cells were further disrupted by five-minute probe sonication with a 50% 
duty cycle at approximately 57 watts using a Misonix (Farmingdale, NY) sonicator. 
Notch, in both membranes and inclusion bodies, was then fully solubilized by the 
addition of Empigen detergent to 3% and tumbling at 4°C for at least 30 minutes. The 
lysate was then centrifuged at 30,000xg in a JA 25.5 rotor (Beckman-Coulter, 
Indianapolis, IN) to remove any remaining insoluble precipitate and unsolubilized 
membranes. 
 Ni-NTA resin (~0.5ml for every 2 liters of culture) was equilibrated with buffer A 
(40 mM HEPES, 300 mM NaCl pH 7.8) plus 1 mM fresh DTT. The volume of resin is 
based on the relatively low expression level of the Notch1 TM/JM; by keeping the resin 
volume low, total non-specific binding of other proteins (relative to tagged TM/JM) to the 
resin is minimized. The equilibrated resin was then added to the supernatant and the 
slurry was tumbled overnight at 4°C. The resin was loaded into a column connected to 
an A280 detector and washed with 10 bed volumes of buffer A containing 3% Empigen 
plus 1 mM fresh DTT, followed by a wash with buffer A containing 1.5% Empigen (% 
v/v) plus 1 mM fresh DTT to rinse all unbound proteins from the resin as judged by the 
return of eluate A280 to a baseline value. Empigen was then exchanged out for the 
detergent lyso-myristoylphosphatidylcholine (LMPC) by re-equilibrating with 12X1 
column volumes (CV) of buffer A with 0.2% LMPC (%w/v) plus 1 mM fresh DTT. The 
column was then washed with successive imidazole washes with buffer A, 0.2% LMPC, 
25 mM imidazole, and 1 mM DTT, followed by buffer A, 0.2% LMPC, 65 mM imidazole, 
and 1 mM DTT. These washes were conducted until the eluate A280 returned to a 
constant value in each case. The LMPC was then exchanged for 
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dihexanoylphosphatidylcholine (DH6PC) with an 8XCV wash of 0.7% DH6PC. The 
DH6PC exchange was followed by a 4XCV exchange step with a 2% DMPC/ DH6PC 
bicelle mixture q=0.33 (DMPC = dimyristoylphosphatidylcholine). The protein was then 
eluted in batch mode by mixing 2.5 ml of elution buffer (2% DMPC/ DH6PC bicelle 
mixture, 300mM imidazole) with the resin and incubating. No DTT is included in these 
buffers due to its weak absorbance at 280 nm, which might introduce error in 
subsequent determination of the protein concentration. The resin was then spun down 
at 500xg in a tabletop centrifuge and the supernatant was collected. This batch mode 
elution method was used because prolonged contact between resin and elution buffer 
resulted in higher yield elution. Alternatively column elution with  high yield can also be 
obtained provided the resin and the elution buffer are allowed to equilibrate briefly in the 
column (no flow) before the elution is allowed to proceed. After elution, the protein 
concentration was determined by measuring A280 and using an extinction coefficient of 
ε=6990 M-1cm-1. 10 mM DTT was added to the sample to reduce any disulfide bonds. 
The molecular weight of the tagged Notch1 TM/JM domain 1721-1771 is 6836 g/mol. 
 Purification was monitored by SDS-PAGE gel electrophoresis. Electrophoresis 
experiments were carried out using an Invitrogen (Grand Island, NY) Novex-Mini Gel 
system and NuPAGE 4-12% Bis-Tris polyacrylamide gels and MES running buffer.  
 
Preparation of Notch1 for NMR Spectroscopy. After purification, the Notch1 TM/JM 
sample is in a 2% bicelle solution, pH 7.8, with 300mM imidazole plus 10 mM free DTT. 
The sample was concentrated by centrifugation at 3700xg using an Amicon Centrifugal 
Filter unit with a molecular weight cut-off of 10,000 Da (Millipore, Billerica, MA). When 
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the volume reached 0.5 ml, 15mM DH6PC in 50 mM NaPO4, pH 6.5 was added, 
returning the volume to 2ml. EDTA was then added to 1mM, and D2O was added to 
10%. This step reduces the imidazole concentration from 300 mM to approximately 
65mM, and DTT to ~2mM. The inclusion of a ca. critical micelle concentration level of 
DH6PC in the buffer serves to replenish the free DH6PC that passes through the 
ultrafiltration membrane during concentration. The pH was then reduced from 7.8 to pH 
5.5 using acetic acid and the solution was then centrifugally concentrated 10X to a 
volume of 0.2 ml and transferred to an NMR tube. Unless otherwise noted, all NMR 
experiments were conducted using 3mm NMR tubes. The final NMR conditions are ~0.5 
mM Notch1 TM/JM, 15% DMPC/DH6PC bicelles (q=0.33), 20 mM NaPO4, 65 mM 
imidazole, 2 mM DTT, and 1 mM EDTA, pH 5.5, and 10% D2O  
 
Isotopic Labeling of Notch1 TM/JM.  Minimal medium was prepared using 1g/L15NH4Cl 
for simple U-15N isotope labeling. For U-15N,13C samples 1g/L of 15NH4Cl was used 
along with 2 g/L of glucose (U-13C6, 99%) (Cambridge Isotope Laboratories, Andover 
MA). Isotopically labeled cells were induced, harvested and lysed as described above. 
In addition to preparing uniformly-labeled samples, we also prepared samples to 
facilitate NMR resonance assignments using an amino acid-selective labeling scheme. 
For this an auxotrophic E. Coli cell strain CT19 was used,205, 206 which has genetic 
lesions in the aspC, avtA, ilvE, trpB, and tyrB genes. These lesions inhibit cell capacity 
to synthesize branched chain and aromatic amino acids. Briefly, cells were grown in 1L 
of minimal media supplemented with 0.5 g each of unlabeled Ala, Asp, Leu, Ile, Phe, 
Val, and Tyr, and 0.1g of Trp as well as 10mg/L ampicillin, 20mg/L kanamycin and 
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tetracycline. The unlabeled amino acids are required for the healthy growth of the cells. 
The use of this auxotrophic cell strain allows for selective labeling of specific amino 
acids while minimizing isotopic scrambling. The cultures were then grown at 37°C, as 
described above until the OD600=~0.85. The cultures were then harvested through 
centrifugation at 3,000xg for 15 minutes. The cells were re-suspended in identical media 
as above except for the inclusion of 0.2 g of 15N-labled valine, leucine or phenylalanine 
in place the corresponding unlabeled amino acid. The cultures were then returned to 
37°C and allowed to grow for 15 minutes, followed by induction with 1 mM IPTG and 
reduction of the temperature to 25°C. The induction time was reduced from the usual 20 
hours to 10 hours to minimize residual isotopic scrambling. The cells were then 
harvested and lysed as above.  
 A reverse labeling scheme was also employed to confirm the identities of 
arginine and histidine peaks. In this scheme, normal U-15N minimal media was prepared 
and inoculated with the regular TM/JM-expressing BL21(DE3) star cell strain as 
described above; however, just prior to induction, 1g/L of unlabled arginine or histidine 
was added to the medium. The TROSY NMR spectrum of the resulting 15N- labeled 
protein contains all the usual peaks except those of arginine or histidine. 
 
Notch1 Backbone Resonance Assignments. NMR spectra were collected at 318K 
(45°C) on a 900 MHz Bruker Avance spectrometer equipped with a cryoprobe. 
Uniformly double-labeled 15N-13C-Notch1 TM/JM was prepared in 15%DMPC/DH6PC 
bicelles, q=0.33, pH 5.5, 500mM imidazole 5mM DTT, 1 mM EDTA and 10% D2O. The 
high imidazole had been used to ensure complete elution of the Notch1 TM/JM. 
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Additional preparations with a reduced (65 mM) imidazole concentration in the final 
samples were later prepared. It was seen that there were no significant spectral 
differences between the low and high imidazole samples. The following three-
dimensional (3D)-TROSY based experiments were carried out: HNCACB, HNCO and 
HNCA.35, 207, 208 
 Selective labeling experiments to resolve backbone assignment ambiguities were 
conducted on 800MHz or 900MHz Bruker Avance spectrometers equipped with 
cryoprobes. Two-dimensional 1H-15N (2D)-TROSY spectra were collected at 318K. 
Samples contained 15% DMPC/DH6PC bicelle, q=0.33, 20 mM NaPO4, pH 5.5, 65 mM 
imidazole, 2 mM DTT, 1 mM EDTA and 10% D2O. 
 All NMR spectra were processed with NMRPipe209 and analyzed with either 
NMRView software210 or Sparky. Secondary structure was estimated using backbone 
chemical shift data and both Talos-N analysis211 and chemical shift indexing.212  
 
Notch1 Relaxation and Backbone Dynamics Experiments. NMR relaxation experiments 
were conducted on a 900MHz Bruker Avance spectrometer at 318K. Samples 
contained 15% DMPC/DH6PC bicelles, q=0.33, 20 mM NaPO4, pH 5.5, 65 mM 
imidazole, 2 mM DTT, 1mM EDTA, and 10% D2O, with approximately 0.5 mM U-15N-
TM/JM. HSQC-based pulse sequences from the Bruker standard library: 
hsqct1etf3gpsi3d (avance-version 12/01/11), hsqct2etf3gpsi3d (avance-version 
12/01/11), and hsqcnoetf3gpsi (avance-version 12/01/11), were used to determine T1, 
T2, and heteronuclear NOE values.  T1 values were extracted from a series of inversion 
recovery experiments with 0.1, 0.25, 0.5, 0.8, 1.2, 2, 4, and 8-second relaxation delays. 
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T2 values were determined using the Carr-Purcell-Meiboom-Gill (CPMG) sequence with 
0.016, 0.032, 0.048, 0.064, 0.080, 0.112, 0.144, and 0.192 second delays. The steady-
state heteronuclear NOE values were determined from peak intensity ratios between 
spectra collected with and without 3 second presaturation.206 All the spectra were 
processed with NMRPipe and analyzed using Sparky. 
 
Paramagnetic Probe Accessibility NMR Experiments. This set of experiments measure 
the accessibility of protein backbone amide sites to water-soluble (Gd(III)-
diethylenetriaminepentaacetic acid) and lipid soluble (16 DOXYL-stearic acid, 16-DSA, 
Aldrich, Milwaukee, WI) probes, as quantitated based on peak intensity reductions due 
to amide site exposure to these paramagnetic probes. A pair of matched 15N-labeled 
TM/JM NMR samples were prepared with 15% DMPC/DH6PC bicelles, q=0.33, 20 mM 
NaPO4, pH 5.5, 65 mM imidazole, 2 mM DTT, 1 mM EDTA, and 10% D2O with ~0.5 mM 
U-15N Notch 1 TM/JM. A 2D-TROSY was taken of the probe-free reference sample. 
After the reference 900 MHz TROSY was collected, Gd(III)-
diethylenetriaminepentaacetic acid (Gd-DTPA, Aldrich, Milwaukee, WI) was added from 
a 100 mM stock to a final concentration of 2 mM. Another 2D TROSY spectrum was 
collected using the same acquisition parameters, including number of scans per 
increment. The peak intensities of each resonance were measured and compared to the 
corresponding peak intensities from the probe-free reference sample. The peak 
intensities were plotted (Figure 3) as an indicator of site access to Gd(III)-DTPA. 
 Using the remaining matched NMR sample, we also assessed site accessibilities 
to the lipophilic probe. For this, 2.5 mM of 16- DOXYL-steric acid (16-DSA) in methanol 
	   68 
was dried in a glass vial, followed by addition of the second 0.2 ml U-15N-TM/JM sample 
and vortexing in the vial until the 16-DSA completely dissolved. This was then 
transferred to a 3 mm NMR tube and a TROSY spectrum was collected using the same 
parameters as for the reference (no probe) and Gd-DTPA samples (above). Peak 
intensities for the 16-DSA sample were compared to the intensities from the reference 
sample and plotted in Figure 3.5. 
 The TM/bicelle interface was probed using 3-cyano-PROXYL (Aldrich, 
Milwaukee, WI), a weakly apolar stable nitroxide free radical. As described above, 
paired samples were prepared with 15% DMPC/DH6PC bicelles, q=0.33, 20 mM 
NaPO4, pH 5.5, 65 mM imidazole, 2 mM DTT, 1 mM EDTA, and 10% D2O with ~0.8 mM 
U-15N Notch 1 TM/JM. 25 mM of 3-cyano-PROXYL in methanol was dried in a glass vial 
and then half of the matched sample was added to the vial and mixed until all the 3-
cyano-PROXYL was dissolved. This was then transferred to a 3 mm NMR tube and a 
15N-1H TROSY-HSQC spectrum was collected using the same parameters as for the 
reference (no probe). The peak intensities of the 3-cyano-PROXYL sample were 
compared to the intensities from the reference sample and the intensity ratios were 
plotted in Figure 3.5. 
 
Water-Amide Hydrogen Exchange. This NMR experiment measured the proton 
exchange rate between the amide backbone residues and water using the CLEANEX-
PM pulse sequence, which eliminates artifacts such as intramolecular NOEs.213 The 
readout for this this experiment is an HSQC (or TROSY) spectrum in which peaks are 
seen only for amide sites that undergo hydrogen exchange with water that is rapid 
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compared to a delay (τ) that is part of the pulse sequence. A sample was prepared as 
above, with 15% DMPC/DH6PC bicelles, q=0.33, 20 mM NaPO4, pH 5.5, 65 mM 
imidazole, 2 mM DTT, 1 mM EDTA, and 10% D2O with ~0.8 mM U-15N Notch 1 TM/JM. 
An HSQC-based pulse program was used with a τ of 25 msec. The CLEANEX-PM-
FHSQC peak intensities were compared to the intensities of an identical FHSQC 
experiment. 
Results and Discussion 
 A number of constructs were explored to determine the best-behaving and most 
informative construct. Initially, a construct extending from Notch 1 residues 1721 (S2 cut 
site) through site 1815 (approximately halfway through the RAM domain) was 
expressed and purified. This construct was found to be unsuitable due to significant 
expression problems. A new series of constructs were then expressed and purified, all 
starting at site 1721 and terminating at: 1758, 1764, 1771, and 1790. These constructs 
expressed more favorably. An N-terminally His6-tagged construct of human Notch 1 
residues 1721 (S2 cleavage site) to 1771 was selected for study (Figure 3.2C) based on 
the facts that it includes both N- and C-terminal juxtamembrane regions, that it 
expresses well in E. coli, and that it yields a well-resolved NMR spectrum in bicelle 
model membranes (Figure 3.2D). While the yield for this construct is not high compared 
to many other recombinant proteins (yield of approximately 1 mg pure protein per liter of 
M9 medium), it does have threefold higher expression than the 1815 construct. 
 There were distinct differences between the TROSY spectrum of the Notch1 
TM/JM in detergent micelles (LMPC) compared to the spectrum in DMPC/DH6PC 
bicelles (Figure 3.1), including many differences in peak positions. The bicelle spectrum 
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(red) includes a few more resonances than the spectrum from micelles (black). 
Moreover, in the micelle spectrum the single tryptophan sidechain (inset) seems to exist 
in two populations: a major population at ~10.2ppm and a minor population at ~10.15 
ppm, suggestive of two conformations or environmental states, whereas only a single 
Trp sidechain resonance is seen in the bicelle case. Given the excellent quality of the 
TROSY spectrum of the TM/JM in bicelles, the increased peak number, the more 
optimal spectral dispersion, and the fact that bicelles are a closer membrane-mimetic 
than micelles, bicelles were selected for the experiments of this work. It was also seen 
that varying pH did not impact the Notch1 TROSY spectrum to a significant degree 
(data not shown). 
 As detailed in the methods above, whole E. coli cell lysates harboring this 
recombinant Notch1 TM/JM were mixed with the harsh zwitterionic detergent Empigen 
to solubilize all membrane proteins, followed by addition of Ni(II)-metal ion affinity resin 
and elution of all non-His6-tagged proteins. The resin with pure bound Notch1 TM/JM 
was subsequently re-equilibrated with lyso-phospholipid micelles and then 
DMPC/DH6PC bicelles to refold the protein, followed by elution of the pure Notch 
TM/JM in bicelles.  
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Figure 3.1.  Notch 1 TM condition screening. 1H-15N TROSY-HSQC NMR spectra 
collected at 800MHz of the Notch1 TM/JM segment in LMPC micelles at pH 5.5 and 
318K (black) overlaid with the spectrum of the same protein in 15% DMPC/DH6PC 
bicelles, q=0.33 (red) at pH 5.6 and 318K. The inlay represents the peaks from the 
indole side chain of the single Trp residue present in the TM/JM. 
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  Following screening (Figure 3.1), optimal NMR sample conditions were 
determined to be 0.5 mM TM/JM in 15% DMPC/ DH6PC bicelle at q=0.33, pH 5.5, 
where the TM/JM-to-(DH6PC+DMPC) mol:mol ratio is approximately 1:600. We then 
conducted NMR experiments at 900 MHz using standard TROSY-based 3D 
experiments (HNCA, HNCO, and HNCACB) in conjunction with both uniform and amino 
acid-selective labeling to accomplish nearly complete backbone and Cβ resonance 
assignment for the TM/JM (Figure 3.2D; BioMagResBank (ID #26565). Exploiting the 
optimal resolution provided by the employment of TROSY-based NMR experiments and 
the modest size of the Notch1 TM construct, it was not necessary to perdeuterate the 
protein to obtain well-resolved 3D NMR data. To resolve any assignment ambiguities 
we used amino acid-selective labeling in order to determine the subset of TROSY peaks 
belonging to specific residue types. We used an auxotrophic cell line CT19 (see 
Methods) to selectively 15N-label valine (6 residues), leucine (6 residues), and 
phenylalanine (5 residues) sites. Except for three of the prolines in the sequence, 100% 
of the peaks in the spectrum were assigned. Due to the nature of the HNCO and 
HNCACB experiments, we also have assignments for two of the five total proline 
residues. 
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Figure 3.2. Notch 1 TM construct information and NMR spectrum. (A) Domain 
organization of full length Notch1. Sites of proteolysis are marked with red. (B) 
Notch1 TM/JM segment with proteolysis sites marked with red. S3 and S4 are γ-
secretase cut sites. C) Sequence of the Notch1 TM/JM segment D) Assigned 900 
MHz 15N TROSY-HSQC spectrum of Notch1 TM segment in 15% DMPC/DH6PC 
bicelles, q=0.33 at pH 5.5 and 318K. Backbone amide 1H-15N peaks have been 
assigned for all of the non-proline residues. The NMR sample included 2mM DTT, 
10% D2O, and 1mM EDTA. A sodium dodecylsulfate-polyacrylamide gel of the 
NMR sample and the single indole side chain 1H-15N peak are shown in the insets. 
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 The secondary structure was then determined using both chemical shift index 
(CSI) and TALOS-N analyses of the chemical shifts.211, 212, 214, 215 The secondary 
structure of the Notch TM/JM was mapped by analyzing the measured Cα, Cβ, and CO 
13C chemical shifts using the program Talos-N (Figure 3.3, upper panel).211  
Predominately α-helical segments were also evident via CSI analysis from plotting the 
chemical shift difference between the Notch1 TM segments Cα, Cβ, and CO chemical 
shift values and standard random coil shift values (Figure 3.3, bottom three panels). It 
appears that most of the TM domain is encompassed by an α-helix that extends from 
residues 1732-1761, with a point of uncertainty being the secondary structure of the 
tetra-proline motif preceding this segment. The flanking JM segments appear to have 
little regular secondary structure (see Figure 3.3). 
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Figure 3.3. Notch 1 TM chemical shift indexing. Upper Panel- Results of using 
TALOS+ to determine the probability of α-helicity for sites in the Notch1 TM/JM 
under bicelle conditions based on analysis of backbone chemical shifts, as 
determined in this work. The lower three panels illustrate the differences between 
the observed chemical shifts and random coil values. The red bars indicate 
places where there is no chemical shift data or prediction. 
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 We also collected NMR R1, R2, and HN-nuclear Overhauser effect (NOE) data, 
which provide insight into the flexibility of the Notch1 TM/JM  (Figure 3.4). Low R1·R2 
and NOE values indicate that sites in the N- terminal JM segment of the protein are very 
flexible, appears to be somewhat more ordered than the N- terminus. The elevated R2 
value for Val1754 is suggestive of local intermediate time scale motions at this site, 
which is interesting given that γ-secretase cleaves Notch between sites 1753 and 
1754.19, 44 Interestingly even in the R1*R2 plot (Figure 3.4); which should eliminate 
anisotropy contributions, the V1754 has an anomalously higher R1R2 value. This 
indicates that this site likely is involved in intermediate time scale motions. This residue 
is next to a G-C-G sequence, possibly explaining why it may be subject to such 
motions.  
 The overall correlation time of the Notch1 TM/JM protein in bicelles does seem 
high especially based on the theoretical values proposed for a similarly sized system.216 
The accuracy of the data acquisition and the fit were confirmed however so it is possible 
that the difference is due to either additional motion or exchange of the helix within the 
bicelle or a systemic factor of 2 error in the dataset. 
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Figure 3.4. 15N NMR relaxation measurements. Measurements collected on a 
900MHz magnet reveal the global dynamics of the Notch1 TM/JM segment in 15% 
DMPC/DH6PC bicelles, q=0.33 at pH 5.5 and 318K. R1 is the longitudinal relaxation 
rate and R2 is the transverse relaxation rate.  Error bars give the uncertainty 
associated with the fits of the relaxation decays to yield the reported values.  
Sites with cyan circles represent peaks with negative values; red circles 
represent either proline sites or instances where extensive peak overlap 
prevented the determination of a reliable value. 
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 We next examined the topology of the TM/JM domain in its bicelle environment. 
A water soluble paramagnetic probe, Gd(III)-DTPA, a lipid soluble probe, 16-DSA, and a 
weakly apolar probe, 3-cyano-PROXYL (that prefers the water-membrane interface), 
were added to bicellar Notch TM/JM samples and the paramagnet-induced intensity 
changes in the TROSY resonances were quantitated. From these data (Figure 3.5) it is 
clear that the TM domain ends at the cluster of basic residues starting at R1758. 
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Figure 3.5. Notch 1 TM Membrane Topology. Membrane topology was probed for 
the 15N Notch1 TM/JM segment in 15% DMPC/DH6PC bicelles, q=0.33 at pH 5.5 and 
318K. A plot of the ratio of site-specific peak intensities from samples containing 
a paramagnet vs. those from a diamagnetic reference sample reveals the probe-
accessibility of each residue. The Gd(III)-DTPA accessibility is in blue and the 16-
DSA accessibility is in red. The bottom panel represents a similar plot using 3-
cyano-PROXYL. Sites with negative bars represent either proline residues or 
instances where extensive peak overlap prevented reliable analysis. 
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Figure 3.6. CLEANEX-PM water exchange experiment. Open circles represent the 
IEXP/IREF of each residue at a mixing time of 25 msec demonstrating areas where 
the amide backbone undergoes exchange with water. Exchange data indicates 
that there is a reduced level of exchange just prior to the tetra-proline residues 
(1728-1731). 
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 The topology near the start of the transmembrane helix at 1732 seems to be 
more complex.  The 3-cyano-PROXYL probe (Fig. 3.5) and NMR CLEANEX-PM 
water/amide hydrogen exchange data (Figure 3.6) indicate that the 1st turn of the TM 
helix at residues 1732-1736 is located at the water-bilayer interface. Moreover, a spike 
in the hydrogen exchange rates at residues 1735-1736 suggests local instability of the 
TM helix.  The results of this experiment (Figure 3.6) elucidate and support the 
conclusions drawn about the Notch1 TM/JM topological orientation in this work. The N-
terminal (1721-1725) residues display rapid exchange with water indicating the residues 
are solvent-exposed. Interestingly, the residues just N-terminal of the tetra-proline motif 
exhibit little-to-no exchange with water occurring on the order of 25 msec or faster. This 
suggests that these residues sit at or slightly below the water-bilayer interface. The 
exchange rate is also seen to be elevated at sites 1735 and 1736, indicating both that 
these sites are located near the water-membrane interface and that there must be some 
local helical instability at these sites, which are part of the TM helix (see Figure 3.3).  As 
expected, the rest of the transmembrane domain exhibits little-to-no hydrogen exchange 
with water until the membrane-cytosol interface is approached, starting near site 1758.  
The intracellular juxtamembrane loop (1759-1768) exhibits fast exchange, followed by a 
dramatic reduction in the exchange rate that is associated with the Leu-Trp-Phe 
segment (1767-1769), which appears to be surface-associated, as supported by the 
paramagnetic probe data shown in Figure 3.5. While the tetraproline segment located at 
site 1728-1731 was not observed in our NMR spectra the fact that the amide sites 
flanking this segment are hydrogen exchange-resistant and inaccessible to all three 
paramagnetic probes might be interpreted to suggest some tertiary structure involving 
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the tetraproline motif and the preceding 1724-1727 segment.  However, it is difficult to 
reconcile ordered tertiary structure with the high dynamics observed for the 1724-1727 
segment (Figure 3.4).  A more plausible explanation is that the Gd(III)-DTPA data for 
this segment is anomalous for a not-yet-determined reason.  If this data is disregarded, 
all other measurements are consistent with a model in which the N-terminus is 
disordered and located in the aqueous phase, but is anchored to the membrane surface 
by the tetra-proline motif, which sits in the water-bilayer interface, oriented 90° with 
respect to the transmembrane domain.   
The short C-terminal JM segment from R1758 to Q1766 is seen to be solvent-
exposed. However, this segment is followed by residues that are significantly 
broadened by 16-DSA and 3-cyano-PROXYL but not by Gd(III)-DTPA, indicating that 
the end of the C-terminal JM segment actually dips back into the membrane as a 
consequence of the Leu-Trp-Phe sequence located near the C-terminus.  This model is 
strongly supported by the water exchange data (Figure 3.6). 
 Even at the very rough level of resolution (Figure 3.7) provided by the data of this 
work it appears that the NOTCH TM/JM is structurally very different from the 
corresponding domain of the APP,35, 36 also a gamma-secretase substrate. APP has a 
kinked TM domain and a C-terminal JM domain that interacts with the membrane 
surface only after a disordered and water-exposed 40-residue segment connecting its 
TM domain to a distal C-terminal amphipathic helix. These features differ from the 
apparently unbroken helix of the NOTCH TM and the short (9-residue) connecting to the 
membrane-interacting C-terminal JM Leu-Trp-Phe segment.  While both APP and Notch 
have N-terminal JM segments that interact with the membrane surface, APP has a 
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surface-bound helix followed by a soluble connecting loop to the TMD, whereas the 
Notch TM helix appears to be preceded by an interfacial tetraproline segment, with no 
connecting water-exposed loop.  While a more complete compare-and-contrast analysis 
of the structures of APP and Notch1 TM/JM domains will await completion of the Notch1 
TM/JM structure, this work suggests that there are significant differences in their 
structures. These differences might be exploited in strategies to inhibit cleavage of APP 
by γ-secretase while still permitting normal (healthy) processing of NOTCH. 
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Figure 3.7. Notch 1 TM/JM preliminary structural/topological model. A basic 
structural and topological plot of the Notch1 TM/JM segment is constructed using 
the experimental data described in Chapter 3. The residues that experienced 
enhanced exchange in the water exchange experiment are ringed with red.  
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IV. The Notch 1 TM Segment is Structurally and 
Biochemically Distinct From C99. 
Introduction 
Alzheimer’s disease is a devastating neurodegenerative disorder that affects millions of 
people worldwide. According to reports by the Alzheimer’s Association, it is thought that 
by 2050, the number of people AD will triple in the United States alone.1 Symptoms of 
AD are generally characterized by a gradual progression of mild cognitive impairment 
and minor physical limitations towards dementia.1 First described in 1907, the etiology 
or mechanism of action of this deadly and devastating disease is still controversial. 
Historically, AD diagnosis occurred after a post-mortem autopsy. The presence of 
extracellular aggregated protein deposits called “amyloid plaques” and severe brain 
vascularization and atrophy characterize late stage AD. Amyloid plaques consist of 
fibrilized proteins the major component being Aβ, the proteolysis product of the amyloid 
precursor protein.3, 4 
 The most prominent model for AD etiology posits that the production and 
oligomerization/aggregation of the Aβ peptide in the brain is the central cause of the 
neuronal damage seen in AD.26-33 APP is proteolytically processed in an “amyloidogenic 
pathway,” where the β-secretase BACE1 excises the extracellular domain of APP. The 
membrane bound enzyme complex γ-secretase then proceeds to cleave the APP TM 
segment (C99) in the membrane to release the Aβ peptide and the APP intracellular 
domain (AICD).8 Due to the promiscuous nature of the γ-secretase complex,13 there are 
multiple cleavage products of C99. Processive cleavage results in Aβ peptide of 
differing lengths. The initial cut occurs near residue 720 with subsequent cleavage 
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proceeding up the helix every three to four residues, until one of Aβ peptides of varying 
lengths dissociates from the active site.14, 15 The most abundant form of the Aβ peptide 
is the Aβ40 with Aβ42/38 being less prevalent. The Aβ42 form is more prone to 
aggregation.24 It is widely thought that the early stage soluble oligomers/aggregates are 
responsible for the neurotoxicity seen in the disease with the end stage aggregates 
being less toxic.25  
 One avenue to prevent Aβ formation would be to inhibit γ-secretase and stop 
proteolysis. Semagacestat, an allosteric inhibitor of γ-secretase, made it to Phase 3 
clinical trials before cancellation.111 Trial participants experienced a wealth of physical 
issues, but perhaps the most troubling was a decline in cognitive capabilities. It was 
determined that the inhibition of Notch signaling was the likely culprit. Notch is one of 
the many known γ-secretase substrates. For another cohort of inhibitors that were 
thought to be “Notch sparing,” clinical trials had to be halted due to Notch induced 
toxicity.112  
 Given the drug development bottleneck that the Notch family of proteins 
precipitates98, 100, 101, 111, 112 closer examination of this protein in the context of AD may 
provide new insights into AD drug development. The NOTCH gene(s) and notch 
signaling occur in all vertebrate organisms.127-130 Notch signaling has been implicated in 
an array of developmental patterning choices.131-134 Notch signaling also controls 
neurogenesis, axon and dendrite growth, and synapse plasticity, as well as neuronal 
death.135-143 
 Similar to C99, Notch undergoes a series of proteolysis steps that prepare the 
protein, prime for signaling and signal activation. Notch begins in the ER as a 
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holoprotein, and trafficks to the Golgi, where the protein is glycosylated and a furin-like 
convertase cuts the protein leaving a dimer of two non-covalently linked domains.156, 158 
The heterodimer is trafficked to the plasma membrane where signal activation can 
occur. In general, the canonical signaling pathway is initiated when mature Notch at the 
plasma membrane has a trans binding interaction with a membrane bound protein 
ligand from a neighboring cell to the extracellular EGF domain of the Notch protein.150 
This binding event triggers trans-endocytosis of the Notch-bound ligand.179 The 
endocytosis induces a force on the Notch extracellular domain that mechanically 
extends the negative regulatory region of the protein (residues 1449-1731).156 This force 
exposes the previously buried S2 cut site to the ADAM 10/17 metalloprotease,182-184 
which cleaves the protein to release the extracellular domain in the committed step of 
the signaling pathway. After the Notch extracellular domain has been cleaved at S2, the 
ectodomain is endocytosed into the signal-donor cell.179, 181 
 After γ-secretase cleavage in the TMD,160 the large Notch intracellular domain 
(NICD)92, 162-164 and a small extracellular peptide (Nβ)161 are released. The NICD 
translocates to the nucleus where it forms a transcriptional activator complex with 
CSL168 and MAML185 that targets a number of different genes.186, 187 The exact 
mechanism of γ-secretase cleavage and cellular compartment is unknown and is an 
active area of research.  
 The γ-secretase substrate C99 has recently been the subject of much study. 
Information regarding the backbone protein dynamics and the positioning of C99 
relative to the membrane has been reported.35 The structure of C99 in detergent 
micelles has been determined and it was discovered that C99 directly and specifically 
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forms a 1:1 complex with cholesterol.36 Further work has shown that C99 is likely 
monomeric under physiological conditions.37 Finally, it has been shown that changes in 
membrane bilayer thickness do not change the overall structure and dynamics of C99 
but does affect membrane topology.38 This extensive list of structural, biochemical, and 
biophysical characteristics has only been collected for C99. We present a complete set 
of data that will allow for a direct comparison of two gamma secretase substrates. In this 
work we present the experimentally determined structure of the Notch 1 TM segment in 
bicelles, test for possible Notch 1 cholesterol binding, and explore its structural and 
topological tolerance of changes in lipid composition. These data complement a 
previously published data set for C99. These data strongly suggest that there are 
significant differences between the Notch 1 TM segment and C99, which can and 
should be exploited in the search for AD therapeutics. 
Materials and Methods 
Expression of Notch1 in E. coli.  Expression of Notch 1 was performed as described in 
Deatherage et. al. 2015.217 Briefly, an expression vector was transformed into E. coli 
BL21(DE3)star cells, and a single colony was used to inoculate a starter culture of LB. 
The starter culture was grown overnight at 37°C. The starter culture (4 ml) was added 
directly to the large-scale culture media grown at 37°C until the OD600 reached 0.8. 
Expression was induced for 20hrs at 25°C, before harvesting. 
Purification of N-Terminal His6-Tagged Notch1 TM/JM (1721-1771).  The purification of 
Notch1 was performed as previously described.217 In brief, lysed cells were solubilized 
by the addition of Empigen detergent to 3% and tumbling at 4°C for at least 30 minutes. 
The solubilized lysate was cleared with centrifugation before being combined with 
	   89 
equilibrated resin and tumbled overnight at 4°C. The resin slurry was loaded into a 
column connected to an A280 detector and washed with a stepwise decrease in Empigen 
before an exchange with the detergent LMPC. The column was washed with two 
imidazole solutions at 25 mM and 65 mM, both containing LMPC. LMPC was then 
exchanged out for the bicelle component DH6PC. The DH6PC exchange was followed 
by a 4XCV exchange step with a 2% DMPC/ DH6PC bicelle mixture q=0.33 (DMPC = 
dimyristoylphosphatidylcholine), before elution with 300 mM imidazole plus bicelles. 
After elution, the protein concentration was determined before 10 mM DTT was added 
to the sample to reduce any disulfide bonds.  
Preparation of Notch1 for NMR Spectroscopy. General NMR conditions of Notch 1 TM 
segment were previously published.217 Purified Notch1 TM/JM sample is in a 2% bicelle 
solution, pH 7.8, with 300 mM imidazole plus 10 mM free DTT was concentrated by 
centrifugation in a buffer exchange step where 15 mM DH6PC in 50 mM NaPO4, pH 6.5 
was added and EDTA was then added to 1 mM. This was concentrated to the desired 
volume for approximately 15% bicelle. The pH was then reduced from 7.8 to pH 5.5 
using acetic acid and transferred to a 3 mm NMR tube. The final NMR conditions are 
~0.5 mM Notch1 TM/JM, 15% DMPC/DH6PC bicelles (q=0.33), 20 mM NaPO4, 65 mM 
imidazole, 2 mM DTT, and 1 mM EDTA, pH 5.5, and 10% D2O. 
Sidechain Assignments. U-15N-13C samples were prepared as previously published.217 
Samples were concentrated as described above. A H(CCO)NH218, 219 and a TROSY- 
based C(CO)NH experiment were run on a Bruker 600MHz magnet. The final NMR 
buffer contained 100% D2O for the HCCH-TOCSY experiment.220, 221 All NMR spectra 
were processed with NMRPipe209 and analyzed with Sparky. Assignments in TROSY-
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HSQC were matched to side-chain carbon and hydrogen chemical shifts. HCCH-
TOCSY was used to correlate side-chain carbon and hydrogen chemical shifts to get 
assignments of side-chain residues in non-deuterated bicelle. 
Cholesterol Titration. These samples were prepared as previously described.36 In brief, 
Cholesterol containing bicelles were prepared by dissolving DMPC and cholesterol in 
chloroform at the desired molar ratio before removing all solvent during lyophilization 
(Labconco, Kansas City, MO). A bicelle solution was then prepared by mixing the 
cholesterol and lipid film with DH6PC and water to form a stock solution of 15mol% 
cholesterol. The stock was heated before undergoing freeze-thaw cycles until a clear 
solution was formed. This stock was used to make identical bicelle solutions that 
contained 0, 2.5, 5, and 10mol% cholesterol. This buffer was used to elute Notch from 
the resin. All samples for NMR were prepared as above with approximately 0.35 mM 
protein in each NMR sample. A 15N-1H TROSY was collected at 318 K for each point on 
a Bruker 900 MHz magnet. 
Membrane Thickness. Membrane accessibility in both DMPC bicelles and in thicker 
bicelles is a method that has been previously described.38, 217 In brief, DMPC, MSM, and 
ESM were weighed in solid form in glass vials at the desired molar ratio. The lipid 
mixtures were then solubilized with <1 ml 95:5 benzene:ethanol stock and lyophilized 
overnight to yield a white powder. After solvent removal, a 2% bicelle solution was 
generated by combining the appropriate amount of DH6PC and water to form a q=1/3 
bicelle mixture. Samples were purified as described above, concentrated to final NMR 
sample form and split in thirds. Three TROSY-HSQC spectra were collected for each 
bicelle condition. The first sample was a paramagnet free reference sample. The 
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second contained 2 mM Gd-DTPA, a water-soluble paramagnet (Santa Cruz 
Biotechnology, Dallas, TX) from a 0.1 M pH 5.5 stock. The third sample contained 2.5 
mM 16-DSA (Santa Cruz Biotechnology, Dallas, TX). 2.5 mM of a 16-DSA stock in 
methanol was dried overnight, the Notch sample was added to the dried film and 
vortexed until the 16-DSA was completely incorporated. All three samples were 
transferred to NMR tubes and subjected to NMR on a 900MHz Bruker NMR 
spectrometer. The peak intensities of each resonance were measured and compared to 
the corresponding peak intensities from the matched probe-free reference sample. The 
peak intensities were plotted as an indicator of site access. 
Paramagnetic Relaxation Enhancement Measurements as Distance Restraints. Wild 
type Notch 1 has one cysteine residue present in the amino acid sequence. For PRE 
measurements two sites were spin labeled. The first was the native cysteine. A second 
site was engineered with site-directed mutagenesis, where the native cysteine C1752 
was mutated to serine and F1744 was mutated to cysteine in the Cys-less background. 
The cysteine mutant was prepared as described. The protein was purified into 0.2% 
DPC. The protein in 0.2%DPC was spin-labeled as described previously.36 In brief, each 
cysteine mutant was concentrated to 0.5 mM and the pH was lowered to 6.5 before 
being reduced with 2.5mM DTT. Spin-labeling proceeded with the addition of the thiol-
reactive probe, MTSL (Toronto Research Chemicals, Toronto, Canada). A twenty-fold 
excess of MTSL was added to a ~0.5 mM Notch 1 sample (buffer: 65 mM imidazole, 2 
mM EDTA, 2.5 mM DTT, 0.2% DPC, pH 6.5). The labeled sample was incubated 
overnight before buffer exchange to prepare for chromatography. The solution was 
mixed overnight with Ni-NTA resin overnight and the resin was then washed with 25 CV 
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of 50mM phosphate, 0.2% DPC, pH 7.8 to remove excess MTSL. The spin-labeled 
Notch was then eluted using the above purification conditions. Spin label sites cover the 
full transmembrane segment and are in generally rigid regions. 
 PRE data was acquired at 900 MHz with sample and parameter matched 
paramagnetic-diamagnetic 1H-15N TROSY-HSQC experiments for the two spin-labeled 
samples. The matched diamagnetic sample was acquired following the addition of 20 
mM ascorbic acid to reduce the paramagnet. Spectra were identically processed using 
NMRPipe 209 and analyzed in SPARKY222 to determine the intensity ratio of the 
paramagnetic versus diamagnetic samples. The intensity ratios and the diamagnetic 
sample linewidths were used to obtain distance restraints as previously described.36, 223, 
224 
NIH-XPLOR Structure Calculation. Restraints used in structure calculations included 
using PRE-derived distances, backbone torsion angles derived from chemical shifts and 
NOE distancerestraints. Backbone Cα, Cβ, CO, and N chemical shifts (published 
previously217) were input into TALOS+ 225 to generate dihedral angle restraints. 
Chemical shift index (CSI) analysis was also used to generate hydrogen bond restraints 
for the TM segment.226 A 3-dimensional (1H,1H,15N)-TROSY-NOESY experiment was 
carried out on U-15N-Notch1 (100 ms mixing time) in DHPC/DMPC bicelles in the 
standard NMR conditions mentioned above to obtain 339 short-, and medium-range 
NOE restraints used in structure calculations. The PRE restraints where employed as 
previously described.227 Briefly, these restraints were classified as close in space if the 
paramagnetic/diamagnetic intensity ratios were less than 0.15 and assigned as being 
between 2 Å to 19 Å apart. Resonances with ratios between 0.15 and 0.85 where 
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converted to distances 223 and given generous uncertainties of ±7 Å. Resonances that 
exhibited little to no PRE effects (intensity ratios greater than 0.85) were loosely 
restrained to be between 19 Å and 100 Å apart. The PRE restraints were implemented 
as NOE-like restraints from the spin label to the backbone amide hydrogen.227, 228  
 Structure calculations were conducted using XPLOR-NIH v2.24229 and performed 
similar to previously published structure calculations.36 [Kroncke, B.M. e.t al, unpublished] 
Simulated annealing was carried out with 15000 steps at 3500 K with cooling to 100 K. 
During the temperature-cooling ramp, the VDW force constant was varied from 0.004 to 
4 kcal•mol-1•Å-4 increased Van der Waals (VDW) interaction potentials.  Similarly, force 
constants were increased for the NOE, and PRE restraints from 1.0 to 30.0 kcal•mol-1•Å-
2. High temperature simulated annealing was followed by torsion angle and full-atom 
minimization steps.  
Structure Refinement with AMBER Molecular Dynamics Simulation. The refinement was 
carried out as previously described. [Kroncke, B.M. e.t al, unpublished]  In brief, ten of the top 1%-
scoring Xplor-NIH-generated Notch 1 structures were selected for further structural 
refinement in an explicit membrane bilayer using restrained molecular dynamics (rMD).  
The starting structures were chosen subjectively such that only the TM region Notch1 is 
located within the membrane bilayer. These ten selected structures were solvated in an 
explicit DMPC bilayer using the CHARMM-GUI server.230, 231 Using GPU-accelerated 
AMBER14232, we began with restrained minimization of each representative structure 
for 30000 steps using steepest descent followed by 30000 steps of conjugate gradient, 
with protein atoms restrained to initial positions. Following restrained minimization, 
structures were minimized without restraints with 1500 steps each of a steep descent 
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gradient followed by a conjugate gradient. With Notch still restrained to initial Xplor-NIH 
coordinates, heating of lipid and water to 10K over 500 steps was performed using 
constant volume boundary conditions and Langevin dynamics with a rapid collision 
frequency (10000 ps-1) to ensure that forces/velocities remained stable. The system 
was then heated to 100K over 2500 steps. The time step was increased from 1fs to 2fs 
for system heating to 318K over 100 ps with constant pressure dynamics and 
anisotropic pressure scaling while the protein and lipid bilayer were restrained. The 
system was equilibrated for 5 ns with NMR restraints applied with a weight of 100%. 
Production rMD at 318K followed for 60 ns, using constant pressure periodic boundary 
conditions, anisotropic pressure scaling, and NMR restraint weight set to 100%. A 
representative structure for each of the ten production trajectories was selected by 
determining which frame contains the Notch structure closest to the mean structure for 
that trajectory. Determining these average structures as well as calculating water 
penetrance and side-chain/lipid interactions employed CPPTRAJ for processing of 
atomic positions across time.233 
Results 
Cholesterol Titration. The importance of cholesterol in AD has been firmly established, 
and it has been proposed that the interaction between C99 and cholesterol may be an 
essential part of the proteolysis of the C99 molecule in lipid rafts.36, 234 The direct and 
specific interaction between C99 and cholesterol suggested an important role for 
cholesterol in partitioning C99 from the bulk plasma membrane into lipid rafts where γ-
secretase cleaves. The role cholesterol plays in Notch biology/biochemistry may well be 
limited and has not been a major research focus of the field. We tested if Notch binds 
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cholesterol. Five samples were prepared with increasing mol% of cholesterol (0 mol%, 
2.5 mol%, 5 mol%, 10 mol% and 15 mol%). HSQC spectra were collected at each 
titration point and were overlaid to monitor chemical shift changes. The overlay is shown 
in Figure 4.1. There were no significant shifts seen in the spectra. After plotting the 
minor chemical shift changes relative to mol% cholesterol, the plots were nearly 
exclusively linear and no residue reached a point of saturation. The minor shifts seen 
are also not restricted to residues in the membrane suggesting the shifts are indicative 
of a more rigid bicelle and a change in the local chemical environment, as opposed to a 
binding event. 
	   96 
 
Figure 4.1. Notch 1 TM cholesterol titration. NMR samples were prepared with 
increasing mol% cholesterol (0, 2.5, 5, 10, and 15 mol% cholesterol).  Sample 
contained ~0.35 mM protein, 15% DMPC/Cholesterol/DH6PC bicelle. The 
experiment was run on a 900 MHz magnet with match experimental conditions for 
each sample. There are no significant chemical shift perturbations that would 
suggest direct binding. 
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Impact of Varying Membrane Thickness on Notch Structure and Topology. The 
positioning of C99 relative to the membrane in detergent micelles was published in 
200835 and in bicelles of varying thickness in 2014.38 The positioning of C99 relative to 
the membrane changed with membrane thickness, and the changes were focused on 
the n-terminal (extracellularly) end of the TM helix. The C-terminal end of the helix was 
un-changed in terms of its location with respect to the membrane surface with 
increasing membrane thickness possibly due to a proposed membrane 
termination/anchor sequence of 3 positively charged lysine residues.38 Topological 
changes induced by membrane thickness may regulate γ-secretase cleavage in both 
C99 and Notch processing. This led us to explore how Notch membrane topology is 
affected by changes in membrane thickness. We prepared three matched samples in 3 
conditions. The first condition was in DMPC bicelles, relatively thin bicelles in which the 
lipid component has two 14-carbon chains; the second was in ESM bicelles, where the 
lipid has two 16-carbon chains; and the third was MSM bicelles, in which the lipid 
component has both a 16- and a 23- carbon chain. The changes in acyl chain length 
significantly increase the bilayer thickness. HSQC spectra of each condition were 
collected and the peak intensity of paramagnetic probe (water- and lipid-soluble) over 
reference intensity was plotted against residue number.  
 The plots of the three membrane thicknesses can be seen in Figure 4.2. These 
plots indicate that the Notch 1 TM segment is structurally tolerant to different bilayer 
thicknesses. The two solid lines represent the helix. There are no significant 
accessibility pattern differences at the C-terminal (intracellular) end of the TM helix and 
the juxtamembrane region as the bilayer thickness is varied. For this segment, probe 
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access patterns are conserved despite the increase in the bilayer thickness. In contrast, 
there are qualitatively different patterns of probe access in the N-terminal region of the 
helix between the bicelle conditions. The thicker bilayer condition is associated with 
greater access to the extracelluar N-terminal end of the TM helix by the lipophilic probe 
16-DSA. The Gd-DTPA effect is more diverse, thus suggesting that the bilayer 
thickness does change only the N-terminal helix positioning not the C-terminal portion. 
This dataset is similar to the results for C99 as presented in 2014.38 Like C99, Notch 1 
also has a series of positive residues (R-K-R-R-R) at the juxtamembrane interface. 
These residues may serve as the Notch 1 membrane anchor sequence. In order to 
confirm the change of bicelle thickness didn’t change conformational structure, 
differences between observed and random coil backbone amide peak chemical shift 
values are plotted in Figure 4.3. There were no significant changes in secondary 
structure in the differing bicelle thicknesses.  
Side-Chain Assignments. Obtaining side chain assignments for membrane proteins 
can be challenging due the size of the protein/lipid mimetic complex and the enhanced 
rate of relaxation.35 Generally, either special labeling schemes are performed to label 
the methyl groups of branched chain amino acids, or expensive deuterated detergents 
are purchased to reduce the proton peak intensity of the lipid chain. In the non-
deuterated DMPC/DH6PC bicelles used in the Notch1 TM studies there are 75 peaks in 
the aliphatic region that are from the bicelle. These signals can easily overwhelm the 
intensity of the side-chain chemical shifts. Using a combination of H(CCO)NH, 
C(CO)NH and HCCH-TOCSY NMR experiments, the chemical shift assignments were 
made for each backbone residue. The HCCH-TOCSY was used to coordinate the 
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identity of the carbon and proton and resulted in 95% of the non-proline side-chain 
atoms being assigned. The two residues left unassigned were either preceding proline 
residues or had a signal too weak to be reliable. The HCCH-TOCSY experiment was 
also used to determine the all trans orientation of the tetra-proline stretch based on the 
chemical shift of the Cβ and the Cγ.235 This all-trans orientation suggests new structural 
information about the tetra-proline motif that in part made up for not being able to do 
more traditional 13C-NOESY experiments to obtain structural restraints for the proline 
residues. 
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Figure 4.2- Membrane Thickness. Notch 1 TM segment was prepared in bicelles 
with 14, 16 or 22 carbons per chain varying the membrane thickness. Water (Gd-
DTPA) or lipid (16-DSA) soluble paramagnetic probes were added and the 
paramagnetic induced change in intensity was monitored per residue in the 
different thicknesses. The solid lines indicate the length of the helix while the 
dotted line marks the region with the most changes in different bicelle 
thicknesses. 
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Figure 4.3- Secondary structure changes. The change in the 15N chemical shift of 
Notch 1 residues compared to random coil was plotted for each bicelle condition. 
There are no significant differences between conditions. 
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 The near complete assignment of backbone and side-chain residues was useful 
in assigning the 1H-1H-15N NOESY-TROSY spectrum, as required for structural 
restraints. The number of backbone-backbone NOE peaks in the NOESY was sparse 
although the side-chain NOE’s were better represented. Using our side-chain and 
backbone assignments, a total of 337 NOEs were assigned with a high degree of 
confidence despite the (obscuring) contributions of lipid-detergent to side-chain NOES 
present owing to the use of non-deuterated bicelles. These NOEs were used as 
distance constraints during structure calculations. 
Structure Determination. A combination of NMR restraints was used to determine the 
bicelle-associated structure of the transmembrane segment of Notch 1. Matched spin 
labeled sample was used to collect a paramagnetic HSQC and a diamagnetic HSQC 
and the difference in the peak intensity was used to obtain distance restraints as 
described in the methods. The NOEs described above and dihedral angles calculated 
from the backbone chemical shift values211, 236 were also used in preliminary structure 
calculation. After initial calculations, a final calculation of 2,000 structures was 
completed and had reasonable convergence. The helical Notch1 TM segment is fairly 
straight, although a non-ideal α-helix. The N-terminal soluble loop samples space 
extensively (Figure 4.4). The C-terminus is far more constrained, at least in part due to 
a kink at the L-W-F motif that is membrane reentrant.217  From the top 1% lowest energy 
models, ten models that did not have soluble domains occupying space where the 
bilayer would be were selected to undergo further refinement in a 60 ns AMBER 
molecular dynamics simulation. Both the X-Plor structures and the Amber refinement 
structures were validated by Procheck.237 A list of restraints, violations and statistics can 
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seen in Table 4.1. When the Notch structures were inserted in the DMPC bilayer prior to 
rMD refinement the tryptophan side-chain were clearly intercalated in the lipid bilayer 
(Figure 4.5). In the refined structure, there is a distorted helix turn at the center of the 
intracellular surface. In Figure 4.6, an example X-PLOR model is compared to the 
refined model. Specific residues are shaded and demonstrate that despite being 
similarly aligned at the start of the helix (A1732), the distortion essentially initiates an 
un-winding of the helix at L1747 shifting the register of the entire second half of the 
helix, which is near the primary γ-secretase cut site (V1754). Interestingly, the overall 
convergence of the structures was not impeded. 
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Figure 4.4- Top 1% of 2,000 structures. The TM helix tightly converges although 
there is significant divergence at the soluble N- and C-terminal segments. 
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Figure 4.5- Average structure of Notch 1 TM during rMD simulation. An example 
of Notch 1 TM structure during 60ns molecular dynamics simulation. There is 
fraying in the C-terminal part of the helix starting with a pronounced helical 
distortion. The re-entrant tryptophan is firmly imbedded in the lipid bilayer. 
Overall, the Notch 1 TM segment is a straight, although, non-ideal α-helix. 
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Table 4.1- Statistics of structural quality. The statistics for restraints, structural 
calculations, and structural quality for 10 lowest energy structures of 2000 
calculated using XPlor and further refined in Amber. 
NMR Distance and dihedral constraints   
 
Distance Constraints 
  
Total NOE 337  
Intra-residue 85  
Inter-residue 244  
Ambiguous  8  
PRE restraints** 81  
Total dihedral angle restraints 
 
70  
Structure Statistics*   
 
Violations 
X-plor AMBER 
Distance constraints (Å) 0.067±0.001 0.121±0.11  
Dihedral angle constraints (°) 1.129±0.064 9.067±1.131 
Average backbone pairwise r.m.s.d. 
(Å)*** 
0.088 0.723 
Ramachandran plot (%)   
Most favored regions 90% 90.9% 
Additionally allowed regions 10% 9.1% 
Generous allowed regions 0% 0% 
Disallowed regions 0% 0% 
*10 NMR structures from the top 1% were used in the calculations. 
**PRE restraints came from F1744C (39) and C1752 (42). 
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AMBER Simulation. The 60 ns simulation refined the X-Plor structure and provided a 
computational model of water entry to the lipid bilayer and Notch 1 TM side-chain-lipid 
interactions. An analysis of the atomic positions over time allowed an average 
calculation of duration of close proximity of each residue with either water or with the 
acyl chain of a DMPC molecule. In Figure 4.7 the average contacts for all ten models 
are plotted for each residue. There is a high level of contact between residues and acyl 
chains in the TM span (1737-1756) (Figure 4.7a). Interestingly, we see a shoulder on 
the curve from residues P1730-F1736. This plot also shows increased contact with lipid 
acyl chains for the re-entrant sequence L-W-F (residues 1767-1769). The result for 
water contact shows the TM segment (1737-1754) is nearly totally devoid of water 
(Figure 4.7b). Interestingly, there is a peak representing water contact at position 1753, 
this would position a water molecule very close to the γ-secretase cleavage site that 
releases the NICD from the membrane.  
Discussion 
 One challenge that arises when trying to develop AD drugs is a lack of 
understanding of the γ-secretase mechanism of action and how this enzyme 
differentiates C99 and Notch as substrates. The data presented in this paper will help to 
clarify some details regarding the differences and possibly inform on whether the γ-
secretase mechanism of action has a substrate conformational structural requirement. 
 
Role of Cholesterol in AD vs. Notch Signaling 
 The interaction and importance of cholesterol in AD has been extensively 
studied.23, 52, 92, 234 Cholesterol is thought to play important roles in AD progression. Our 
	   108 
observed lack interaction between the Notch 1 TM segment and cholesterol was not 
surprising. The majority of research examining lipids and lipid requirements in Notch 
signaling has been focused on cellular trafficking and endocytosis rather than an 
interaction between Notch and cholesterol. Research has shown that non-cannonical 
Notch signaling can be stimulated by endocytosis and initiated by an E3 ligase with an 
unknown mechanism.238 Further, depending on the endosomal stage, levels of this 
basal, non-canonical signaling can be tuned.239 In 2014, the Baron group reported that 
cholesterol added or depleted from culture media was able to change the cellular 
location of Notch activation in this non-canonical signaling pathway.240 They did not 
posit a mechanism of how cholesterol was changing Notch signaling, but based on our 
titration results it is likely an indirect effect, unlike the C99-cholesterol relationship. It is 
possible that changing the membrane cholesterol levels may alter clathrin and AP-3 
endocytosis241 and thus change Notch trafficking.  
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Figure 4.6- X-plor vs. AMBER comparison. Comparison of the starting X-PLOR 
determined structure to the AMBER refinement average structure. Specific 
residues are labeled and shaded lighter blue to emphasize the changes in the 
refined structure. Notice the shift in helical register starting at L1747 not present 
in A1732. 
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Membrane Thickness 
 
 It is known that the production of Aβ is controlled by the function and regulation 
of γ-secretase. This membrane bound complex is sensitive to pH,242, 243 membrane 
thickness, chain length, saturation and lipid head group.92-94 Because of this, the lipid 
microenvironment and the cellular compartment that γ-secretase is occupying at the 
time of enzyme/substrate interaction may regulate function. Based on previously 
published data it is easy to speculate that the kink in the C99 structure provides 
flexibility that allows C99 to straighten out in thicker membranes without changing the c-
terminal membrane anchor position, a mechanism that would explain the changes in 
paramagnetic accessibility with changing membrane thickness. This would likely change 
the position of C99 in the active site of γ-secretase. This may be one potential way to 
regulate proteolysis. The straighter and more rigid helix of Notch217 does not have this 
capability. During the course of the AMBER simulations, the TM segment seems to 
laterally diffuse through the membrane, sitting at an angle within the membrane as 
opposed to the perpendicular orientation relative to the plane of the membrane. This 
angled positioning would allow for a greater membrane thickness tolerance as the angle 
of the helix could adjust with changing bilayer thickness. It is also possible that some of 
the accessibility ambiguity comes from multiple populations of Notch1 at different angles 
within the bicelle resulting in an average accessibility seen in Figure 4.2 as opposed to 
a single conformational accessibility. This Notch flexibility would suggest that a 
therapeutic that would prevent C99 from entering the preferred cellular compartment for 
γ-secretase cleavage, or that prevents C99 from adjusting to the bilayer thickness, thus 
changing γ-secretase cleavage, would not have a major impact on Notch processing. 
	   111 
Figure 4.7- AMBER analysis. Analysis of residue contact with lipid acyl chain (A) 
and water (B) during 40 ns rMD simulation. 
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Amber Model 
 
 The average Notch helix after the rMD refinement is a non-ideal helix. Largely 
remaining a straight helix, the distortion around residues 1746-1748 seemingly tightens 
the N-terminal portion of the helix leaving a frayed or unwound C-terminal portion. This 
helical distortion gives the appearance of a bend or a kink in the helix. Interestingly, this 
may better help to position Notch at the active site of γ-secretase and limit steric clashes 
between the straight Notch helix and the loop between presenilin helix 3 and 4 
surrounding the active site. The presence of water seen in the membrane during the 
rMD simulation suggests an unstable helix. The water molecule at position 1753 water 
could serve to solvate the helix after proteolysis or to compensate for broken hydrogen 
bonding that may result from the distorted helical turn. The clustering of waters around 
the N-terminal helix at least partially supports the water exchange data previously 
published.217 The differences seen are likely due to the difference in timescale (ns vs. 
ms).217 The near consistent close proximity of the tryptophan residue to the lipid chains 
of the bilayer in the simulation suggest that the membrane penetrance by the re-entrant 
L-W-F sequence is energetically reasonable and supports the membrane accessibility 
data presented previously.217 Interestingly, the shoulder seen in Figure 4.7a is the same 
region of the TM helix that has an ambiguous data in Figure 4.2.  This region is the most 
N-terminal portion of the helix, and there is a level of ambiguity regarding positioning 
within the membrane. This simulation confirms earlier hypotheses that these residues 
sit very near the surface of the membrane and may also sample outside of the 
membrane. 
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Figure 4.8- Comparison of C99 and Notch 1 TM in DMPC bilayer. C99 and Notch 1 
have distinctly different structures. 
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Conclusion 
 The biochemistry of Notch and C99 is very different. The work presented in this 
paper further demonstrates this by showing Notch has no interaction with cholesterol 
and seems to have a totally different mechanism for adjusting to different membrane 
compositions/thicknesses than C99. Furthermore, the structures of Notch and C99 are 
very different. Comparing the two experimentally determined structures from simulated 
annealing (Figure 4.8), the significant differences in the transmembrane segment are 
apparent. C99 has a pronounced kink centered around 708/709 and decided surfaces. 
The Notch structure is a straight helix with a distortion in the helix seen in the rMD 
simulation that shifts the register of the helix near C-terminal end of the helix. The 
DeGrado lab has designed peptides that can bind specific integrin TM segments and 
small molecule inhibitors that can recognize mutations.244, 245 These methodologies 
could potentially be used to capitalize on the distinct differences between C99 and 
Notch and that should be sufficient to engineer small molecule drugs that can 
specifically recognize proteins based on minor structural differences. In the case of 
differentiating Notch and C99, the differences are more than minor. With the completion 
of this work, there is now a complete dataset for the Notch 1 TM segment that 
compliments the accumulated data already known about the protein C99. With the 
complete datasets for both Notch 1 and C99, there should now be sufficient information 
to draw new insights into not just how γ-secretase functions, but also inform possible 
drug therapies that can specifically target APP and C99 while sparing the essential 
function of Notch. 
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V.	  Discussion and Future Directions 
γ-Secretase Activating Protein 
 Ultimately, despite initial optimism, the GSAP work of the Sanders lab did not 
progress beyond the published manuscript described in Chapter 2 due to the 
unexpected challenges in working with recombinant GSAP.  The overall instability of the 
protein and the unexpected requirement of detergent, despite being a soluble protein 
led us to question the stability and folded-ness of the protein. In the imatinib pull-down 
assays in which GSAP was discovered, it is possible that were other protein factors, 
that are essential for GSAP folding or functionality. Given that the entire panel of pull-
down results were not published in He et. al.,123 it is possible another protein co-factor 
was pulled down and was simply missed in the original screen. This would suggest that 
the in vitro protein that was purified was lacking an essential component that is needed 
for stability and possibly for the interaction with or the efficacy of the imatinib interaction. 
Given the detergent requirement in the purification (Deatherage et. al.)246, it is also 
possible that GSAP is a lipid binding protein and there is a lipid co-factor.  
 Lipid binding proteins carry out a great number of different functions.247-249 Since 
GSAP was expected to be a soluble protein, even if it binds lipids, it would be similar to 
other members of the lipid binding family. Folding upon lipid binding could make sense 
mechanistically given that APP and γ-secretase are generally considered to be 
associated with lipid rafts.234 Lipid binding may be how GSAP is able to localize to its 
binding partners. GSAP does have a cholesterol-binding (CRAC) motif.250, 251 If the 
CRAC motif does truly bind cholesterol, then the localization of APP and γ-secretase to 
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cholesterol rich microdomains would support GSAP being in close proximity to the other 
proteins. 
 As a future direction, obtaining a stable folded protein is essential. It would 
potentially be worthwhile to pursue condition testing that focuses on having lipids 
present. It would be interesting to see if the presence of cholesterol, sphingomyelin, 
phosphoethanolamine, or synthetic phosphocholine or phosphglycerine in a lipid bilayer 
mimetic would make a difference in the protein stability, activity or folded state. If it 
made a difference, it would suggest that the lipid presence makes a significant 
difference in protein stability. 
GSAP Follow-up Research and Controversy 
 Following the 2012 Sanders Lab publication, subsequent papers came out that 
cast the GSAP story in a new light. In 2013, a Journal of Biological Chemistry paper 
was published that sought to further characterize the role of GSAP in imatinib regulation 
of γ-secretase.252 In this paper, the researchers sought first to reproduce the finding of 
the original GSAP paper,123 and then to extrapolate further. As in the original paper, 
siRNA knockdown of endogenous GSAP resulted in a reduction of Aβ levels. When the 
researcher hypothesized that overexpression of GSAP should increase Aβ levels, they 
were surprised that the results in different cell lines did not bear this hypothesis out. 
They found over expression of full-length GSAP and the reported 16kDa form reduced 
the levels of Aβ in some cells, but in N2a cells (used in He et. al.), GSAP did not change 
Aβ levels.252 
 In the original GSAP paper, the authors postulated that GSAP has a direct and 
specific interaction with the C-terminal domain of APP, called C99. Similar to the result 
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described in Chapter 2,246 the authors performed a GSAP IP that failed to pull down 
either C99 or any components of γ-secretase. The reverse C99 IP did pull down γ-
secretase components, but not GSAP.252 These researchers also purified recombinant 
GSAP, which had a detergent in the final buffer, similar to the purification described in 
Chapter 2. They used this recombinant protein in an in vitro γ-secretase assay, where 
the addition of purified GSAP had no impact on the levels of either Aβ or the AICD.252 
Due to the inconsistencies the researchers saw between in vitro assays and in vivo 
assays and between their data and the data published in the original paper, the authors 
suggested that the GSAP story was more complicated than it originally seemed, 
consistent with our results. 
 In 2014, another paper, this time from the lab of Kai Blennow, shifted the focus 
back to imatinib as a possible drug compound lead. These researchers noticed that the 
GSAP paper and the Netzger paper used animal models and cellular assays; there was 
no exploration of how imatinib would change Aβ levels in human patients. They then 
collected plasma samples from >20 patients with either chronic myeloid leukemia (CML) 
or AD. The CML patients were about to begin a one-year treatment course with either 
400 or 600 mg of imatinib. Plasma samples were drawn regularly over the course of the 
year, at 3, 6, 9 and 12 months. The AD patients had plasma drawn at the baseline time 
point and at the year mark.253 In the CML cohort which had very low Aβ levels, the 
Blennow group saw an increase in Aβ levels at the 3 month time point which then 
normalized for the remainder of the year. This was the same in both the low (400 mg) 
and the high dose (600 mg) patients. The AD patients had steady levels of Aβ from 
baseline to the 12-month time point.253 The researchers also saw no change in Aβ 
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levels with increased dosage of imatinib in cultured cells. This led the researchers to 
conclude that, in humans, imatinib was not significantly impacting Aβ levels and 
therefore, both imatinib and GSAP are unlikely to be good targets for AD 
therapeutics.253 
 It is important to briefly discuss that even before the GSAP theory was advanced 
in 2010, there were at least two opposing theories regarding how imatinib was able to 
lower Aβ levels. The first theory, published by the Wolfe group in 2005, investigated the 
role that nucleotides played in γ-secretase activity. They found that the purity of the 
Gleevac drug changed how the γ-secretase activity was inhibited. Fully purified Gleevac 
did not inhibit γ-secretase activity. They reported a number of additional compounds 
found in commercially available Gleevac, and suggested that one of these molecules 
was the actual inhibitory molecule.254 In 2007, the Kilger group published a different 
theory. They reported that the effects of imatinib are independent of γ-secretase 
inhibition.255 In this publication, the Kilger group presented a model where Gleevac was 
able to reduce Aβ through the action of neprilysin, a metalloprotein that degrades Aβ.256 
The Kilger group proposed that Gleevac increased the AICD by slowing the peptide 
turnover. This increase enhances neprilysin expression and the increased protein levels 
are then able to clear more Aβ, thus lowering the overall amount without changing γ-
secretase activity or affecting Notch processing.255 These theories are very different 
from the mechanism laid out in the GSAP paper. 
 The contradictions and inconsistencies between different groups investigating 
imatinib and GSAP led to a report covering the issue in Alzforum, in early 2014.257 In 
this article the author reported at least 8 groups attempted to reproduce the original 
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GSAP work, and none were successful. Paul Greengard, the corresponding author of 
the original paper suggested that the real problem with the failed attempts was that 
other researchers were not exactly duplicating experimental conditions and this was 
where the contradictions came from.257 This opened a discussion regarding scientific 
reproducibility and how closely labs should have to follow original methods to get 
identical results. Another question arose regarding the dissemination of negative or 
contradictory data. The original paper was published in the journal Nature, which has a 
large impact factor and a powerful reputation. The three papers that contradicted this 
work were published in Biochemistry, Journal of Biological Chemistry, and Alzheimer’s 
& Dementia. These journals have excellent reputations but are not as widely cited or 
read as Nature. According to the Alzforum report, Blennow attempted to publish his 
imatinib study in Nature as a BCA (Brief Communication Arising), but after consulting 
with the original authors, Nature elected not to publish the paper. This leads to 
interesting questions about journal’s roles in being impartial and disseminating negative 
data or opposing research. To paraphrase a quote from the Alzforum report by a 
leading AD researcher Bart deStrooper “…negative or contradictory data is important 
and needs to be published at the same level as the original paper…”257 
 Despite the controversy discussed in this section and the contradictory papers 
published in 2012, 2013, and 2014, GSAP is still mentioned as a viable drug target in 
reviews, and people are still trying to learn more about this molecule. In fact, new 
papers have been published that explore the GSAP/imatinib relationship. One such 
paper suggested that in mice, imatinib acts in GSAP expression and lowers Aβ and tau 
phosphorylation.258 Another paper explored GSAP degradation and determined that 
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GSAP is ubiqutinated and degraded by the proteasome.259 Another publication 
proposed that Caspase 3 modulates GSAP.260 These new papers don’t render the 
contradictory papers moot, and the controversy regarding GSAP will likely remain until 
either a lab is able to replicate the results seen in the original paper or GSAP is 
determined to be unimportant to AD pathology. 
Notch 1  
Structure 
 The Notch 1 TM segment structure detailed in Chapter 4 is the first 
transmembrane segment structure that has been determined in the Notch field. There 
are four Notch family members and the Notch family ligands; Jagged and DSL, are also 
type 1 membrane proteins. Prior to the Notch 1 TM studies, the bulk of the structural 
work being done has been on the soluble domains of these proteins. A summary of the 
structures published as of 2008 was published in the Journal of Cell Science.169 One 
avenue of future research will be to determine the structures of the missing TM 
segments using the purification strategies detailed in Chapter 3.217  A table of possible 
structural targets can be seen in Table 5.1. It would also worthwhile to determine if 
computational methods could be used to model a reconstructed version of full length 
Notch using the published structures as a way to better model and visualize the 
proteolytic processing that occurs during Notch signaling.  
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Table 5.1- New TM segment targets 
Target Name Uniprot ID Approximate TM Span* 
Notch 2 Q04721 1678-1696 
Notch 3 Q9UM47 1644-1664 
Notch 4 Q99466 1448-1468 
Jagged 1 P78504 1068-1093 
Jagged 2 Q9Y219 1081-1101 
Delta-like protein 1 (Dll1) O00548 546-568 
*Proposed TM span from Uniprot entry. 
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Notch and Disease 
 Beyond the confounding role that Notch plays in AD pathogenesis, Notch and 
associated signaling have been implicated in a number of different serious diseases.  
The loss of Notch function, either due to mutation in the Notch ligand binding domain or 
in the ligand itself can cause an array of developmental disorders including Alagille 
Syndrome, and heritable congenital heart defects.261-264 In the case of stroke or 
traumatic brain injury, the ischemic neuronal injury/death prognosis can be worsened by 
Notch activation worsening inflammation.265 Notch signaling controls tumor progression. 
204, 266, 267 There have been preclinical studies that use γ-secretase inhibitors suggesting 
that changing Notch signaling may be a way to disrupt cancer progression. 268, 269 
Mutation in the NRR of Notch can cause T-cell acute lymphoblastic leukemia (T-ALL) by 
deregulating Notch signaling.159, 270, 271 There is even evidence to suggest that there is 
hyperactivation of Notch signaling in AD and Pick’s disease.272 
 There is now a wealth of biochemical and structural data that are known about 
the Notch 1 TM segment and the soluble domains. A future research endeavor should 
be to design a small drug or peptide that would bind specifically to the TM segment to 
inhibit γ-secretase cleavage and could be used immediately after stroke and during 
cancer chemotherapy treatment to prevent damaging inflammation and tumor 
metastasis. There is evidence that small changes to a TM helix structure are sufficient 
for drug specificity.244, 245 As such, a drug could be made to prevent incidences of illness 
where overactive Notch signaling causes disease without necessarily inhibiting the 
Notch signaling otherwise required for functionality. 
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Figure 5.1- Clustal sequence alignment of the human Notch family 
transmembrane segments. The level of conservation is marked by darker shade. 
Arrows mark the absolute conservation of the S2 cut site, the “membrane 
anchor” sequence, and the re-entrant tryptophan sequence. 
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Notch Family Sequence Conservation 
 The Notch 1 TM segment characterization work described in Chapters 3 and 4 is 
the first time structural and biophysical characteristics of the transmembrane segment of 
a member of the Notch family has been investigated in depth. Only the TM segment of 
Notch 1 has been determined, so it is challenging to assess how many structural and 
biochemical similarities can be inferred for the other members of the Notch family. As 
mentioned in Chapter 1, Notch 1-4 vary in both the number of EGF repeats and in the 
presence of the transcriptional activation domain (TAD). These proteins also have 
different TM segments. A Clustal W273 sequence alignment of the four human Notch 
proteins can be seen in Figure 5.1. There are three sites of absolute conservation 
across the family. The first is at the S2 cut site.  
 The second site of conservation is at the membrane anchor arginine(s) at the 
juxtamembrane (discussed in Chapter 4). This conservation of both arginine positioning 
and overall charge state in the same position support the hypothesis that this positive 
charge serves to anchor the C-terminal position of the helix relative to the membrane. 
This would help to position the helix at the approximate position to be cleaved by γ-
secretase. Changes to the charge state of this stretch of positively charged residues 
would possibly change the positioning of the molecule in the membrane shifting the γ-
secretase cut site and thus the NICD. It has already been reported that mutating 
Lysine1759 to arginine shifts the S3 cute site and forms an unstable NICD with weaker 
signaling.274 The data in Chapter 4 (Figure 4.2) shows changes to membrane thickness 
only change the N-terminal helix topology pattern not the C-terminal. It is possible that 
disrupting the membrane anchor would change the C-terminal positioning and alter γ-
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secretase cleavage. This would be an avenue for future research to pursue: determining 
how lipid composition (and thus cellular compartment95) would change Notch topology 
and NICD generation across that Notch family, which could serve to better our 
understanding of Notch signaling. 
 The third site of absolute conservation is in the intracellular juxtamembrane 
region. In Notch 1 there is a L-W-F sequence. The L-W is conserved and the third 
position is conserved for residues with strongly similar chemical properties. This stretch 
of residues has been shown to re-enter the lipid bilayer (discussed in Chapter 3).217 The 
molecular dynamics refinement in AMBER (Chapter 4, Figure 4.7a) also shows a 
distinct kink at those residues, and the tryptophan residue is firmly inserted in the bilayer 
and does not leave the membrane during the 60ns simulation. It is likely that the other 
Notch family members have a similar re-entrant kink. This part of the protein is 
technically part of the RAM domain. Determining what function this amphipathic region 
has, and whether mutating it would alter the ability of the RAM domain to bind the 
transcription factor-binding partners would allow us to better understand what 
physiological role this amphipathic region has and why it would be conserved. It is also 
possible that these residues position the intracellular NICD domain away from γ-
secretase during cleavage by serving as an anchor position distal to the active site. 
Determining if mutagenesis of these residues changes γ-secretase cleavage would 
assess whether these residues are more important to Notch and notch signaling than 
had previously been considered.  
 The remainder of the helix has regions where the sequence is moderately 
conserved, namely in overall chemical properties (see Figure 5.1), especially in the 
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center of the helix. Given that the Notch 1 structure is a generally straight helix 
(although not an ideal α-helix), it would be valuable to determine the structure of the 
other three Notch proteins to see if the structure of the other three would resemble 
Notch, or if they would demonstrate curvature, a kink, or dynamic flexibility like C99.35, 36 
Determining the structure of the different members of the Notch family would help to 
assess the γ-secretase-substrate interaction in different cell types due to variable Notch 
family tissue expression. 
Docking and Molecular Dynamics Analysis of γ-Secretase and Substrate 
Interactions  
 Until late 2015 there was no atomic resolution structure of the complete γ-
secretase complex. With the new γ-secretase structures and the experimentally 
determined structures of C99 and Notch, docking studies can be done to interrogate the 
differences in the substrate cleavage. Future docking studies could also be performed 
as more γ-secretase substrate structures are published. The Sanders group has 
structures of 2 members of the KCNE modulatory protein family. These proteins were 
listed as a substrate in Table 1.1, but γ-secretase cleavage is not a big part of the 
literature. It would be worthwhile to pursue the docking to determine if the docking of 
these predicted substrate would resemble the docking of the better known substrates 
Notch and C99.  
 Additional and more comprehensive studies should be performed to model the γ-
secretase processivity that characterizes the proteolysis. It would also be interesting to 
determine if molecular dynamics simulations could reproduce the different confirmations 
that the Shi group found in their cryo-EM structural analysis of γ-secretase.97 
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Additionally, a simulation could map the helical trajectories that underlie the 
conformational changes that γ-secretase must undergo to bring the active site aspartate 
residues close enough to perform chemistry. 
 The connection between γ-secretase and lipid rafts has been well established.234 
Another research question to pursue with molecular dynamics simulations would be to 
assess the role that lipid rafts and cholesterol play in the organization and flexibility of 
the γ-secretase complex. Bai et. al. used careful cryo-EM reconstructions to show 
multiple confirmations of the γ-secretase active site.97 They did not explore what the 
membrane organization and plasticity would do to moderate the flexibility of the γ-
secretase complex. Figure 5.2 is a cartoon model of how the γ-secretase complex with 
substrate may be different in the bulk plasma membrane (top) and how the complex 
may change in lipid raft where the cholesterol and the sphingmyelin molecules serve to 
organize and rigidify the membrane (bottom).  
 It is possible that the flexibility of the bulk membrane allows for the multiple 
confirmations seen in the Bai et. al. paper. This flexibility also suggests that the active 
site confirmation could shift and change depending on the allowances of the membrane. 
Further, since it has been shown that in thicker membranes, only the n-terminal part of 
the helix is changed in C9938 and in Notch (Chapter 4), this may suggest a concomitant 
change in γ-secretase. By first docking γ-secretase and the substrate to fully sample the 
conformational space, the models could then be computationally inserted into 
membranes enriched with cholesterol and sphingomyelin. The positioning of the 
substrate C-terminal residues could be enforced and molecular dynamics simulations 
could be run to explore the membrane induced conformational changes. These 
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simulations would not only further explore the γ-secretase active site, but would also 
provide information on the functional difference of γ-secretase in lipid rafts and outside 
of them that could be correlated to experimental data. 
 Another potentially helpful avenue of future research would be to use 
computational mutagenesis targeting how familial AD mutations in both C99 and in 
presenilin275, 276 impact the structure and interactions of both C99 and γ-secretase. It is 
possible that these mutations induce structural changes that alter γ-secretase function. 
Determining the feasibility of an in silico drug screen to investigate small molecule 
compounds that might mitigate AD processing may also be a promising avenue of 
research that could result in a therapeutic possibility. 
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Figure 5.2- Lipid raft induced structural perturbations. It is possible that there are 
differences in the structural organization of γ-secretase in the bulk membrane 
(top) and in the ordered lipid rafts (bottom). The thicker and more rigid membrane 
may not only position the substrate differently but may change the orientation of 
the active site.  Green lipid=sphingomyelin, pink=cholesterol, star=active site, 
blue=substrate. 
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Significance and Impact 
 The goal of this doctoral thesis project has been to explore and characterize the 
etiology of Alzheimer’s disease. Multiple roads of inquiry were undertaken, but 
ultimately, this dissertation has detailed the work done towards characterizing proteins 
that are related to Alzheimer’s disease. The characterization of GSAP, originally thought 
to regulate the processing of C99, in Chapter 2 clearly laid out the biochemical and 
preliminary structural characterization of the GSAP protein as well as why the project 
was terminated. The GSAP discussion in Chapter 5 further details problems with GSAP 
research that arose after the characterization was published. This details how issues of 
reproducibility and conflicts in the field have stymied the progress towards targeting 
GSAP as a viable AD therapeutic and how these issues need to be resolved before 
genuine progress can be made.  
 The lack of knowledge about biochemical and structural characteristics of the 
Notch protein, which has significantly confounded Alzheimer’s disease drug 
development, led to the second major project described in this dissertation. Chapter 3 
details the cloning, expression, purification, and initial NMR characterization of the 
transmembrane segment of the human Notch 1 protein. Chapter 4 details the structure 
determination process, Notch tolerance to bilayer thickness, cholesterol binding and a 
molecular dynamics simulation of the Notch molecule. The Notch structural studies add 
new knowledge on how to further differentiate Notch and C99 during the treatment of 
Alzheimer’s disease and open new pathways of research towards drug development. 
Previously there was little to no structural or biochemical information about the Notch 1 
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TM segment. The work presented here provides the first structural information regarding 
the TM segment, which will will allow for better and more carefully designed studies in 
the future that can rely on the structural datasets. 
 In general, one challenge in the AD field is that there are disparate bodies of 
knowledge regarding disease pathology and etiology, but that are rarely merged or 
thought about in the context of planning for further study. In this work I present a 
potential new way to approach the AD field, in which real focus and attention are 
devoted to bridging disparate bodies of knowledge (i.e., regarding C99 and Notch) and 
creating a more broadly integrated body of knowledge for both datasets. This approach 
provides new information regarding the biochemical and structural differences between 
C99 and Notch 1, which may provide a new platform for the development of C99-
specific therapeutics.  
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